Oliver v. Secretary of Health and Human Services

In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
Case No. 10-394V
Filed: February 1, 2017

* * * * * * * * * * * * * UNPUBLISHED
LAURA OLIVER and EDDIE *
OLIVER, JR., Parents and Legal * Chief Special Master Dorsey
Representatives of E.O., III, *
* Ruling on the Record; Entitlement;
Petitioners, * SCN1A Gene Mutation; Severe
* Myoclonic Epilepsy of Infancy
v. * (“SMEI”); Dravet Syndrome;
* Chronic Complex Partial Seizure
SECRETARY OF HEALTH * Disorder; Diphtheria-Tetanus-
AND HUMAN SERVICES, * acellular Pertussis (“DTaP”);
* Hepatitis B (“Hep B”); Inactivated
Respondent. * Poliovirus (“IPV”); Pneumococcal
* Conjugate (“PCV”); Rotavirus
* * * * * * * * * * * * * Vaccines.

Clifford J. Shoemaker, Shoemaker and Associates, Vienna, VA, for petitioners.
Lara A. Englund, U.S. Department of Justice, Washington, DC, for respondent.

DECISION 1

On June 25, 2010, Laura Oliver and Eddie Oliver, Jr. (“petitioners”), filed a petition for
compensation on behalf of their son, E.O. III (“E.O.”), under the National Vaccine Injury
Compensation Program (“the Program” or the “Vaccine Act”). 2 Petitioners alleged that E.O.
developed a fever and febrile seizures, that he continued to experience seizures, and that he

1
Because this decision contains a reasoned explanation for the undersigned’s action in this case,
the undersigned intends to post this ruling on the website of the United States Court of Federal
Claims, in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 note
(2012)(Federal Management and Promotion of Electronic Government Services). As provided
by Vaccine Rule 18(b), each party has 14 days within which to request redaction “of any
information furnished by that party: (1) that is a trade secret or commercial or financial in
substance and is privileged or confidential; or (2) that includes medical files or similar files, the
disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule
18(b).
2
The National Vaccine Injury Compensation Program is set forth in Part 2 of the National
Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended,
42 U.S.C. §§ 300aa-10 to -34 (2012). All citations in this decision to individual sections of the
Vaccine Act are to 42 U.S.C. § 300aa.

1
ultimately developed a chronic complex partial seizure disorder as a result of receiving the
Diphtheria-Tetanus-acellular Pertussis (“DTaP”), Hepatitis B (“Hep B”), Inactivated Poliovirus
(“IPV”), Pneumococcal conjugate (“PCV”), and Rotavirus vaccines on April 9, 2009. See
Petition (ECF No. 1) at ¶¶ 5, 6. Respondent recommended against awarding compensation to
petitioners. See Respondent’s Report (“Resp’s Rep.”) dated July 29, 2011 (ECF No. 40) at 15.

Medical records reflect that E.O. was born with a mutation of his SCN1A gene and that
he has a seizure disorder known as Dravet syndrome. To date, there have been at least 15 other
Program cases which involved children with SCN1A mutations, and compensation has been
denied in all of these cases. 3 As in the other cases, petitioners’ expert opines that the SCN1A
mutation made E.O. susceptible to developing Dravet syndrome, that a gene-environmental
interaction is at play, and that the vaccinations trigger that interaction. Respondent asserts that
E.O.’s mutation is the sole cause of his Dravet syndrome and his resulting neurological
condition.

The undersigned agrees with respondent that E.O.’s SCN1A gene mutation is the reason
that he has Dravet syndrome and its associated neurological condition and finds that petitioners
have failed to show by preponderant evidence that E.O.’s injuries were caused by his April 9,
2009 vaccinations. Although E.O.’s vaccinations may have caused a fever or otherwise triggered

3
Faoro v. Sec’y of Health & Human Servs., 10-704V, 2016 WL 675491 (Fed. Cl. Spec. Mstr.
Jan. 29, 2016), review denied 128 Fed. Cl. 61 (2016); Barclay ex rel. Ramirez v. Sec’y of Health
& Human Servs., 07-605V, 2014 WL 7891493 (Fed. Cl. Spec. Mstr. Dec. 15, 2014); review
denied 122 Fed. Cl. 189 (2015); Santini et al. v. Sec’y of Health & Human Servs., 06-725V,
2014 WL 7891507 (Fed. Cl. Spec. Mstr. Dec. 15, 2014); review denied 122 Fed. Cl. 102 (2015);
Waters v. Sec’y of Health & Human Servs., 15-320V, 2015 WL 3898079 (Fed. Cl. Spec. Mstr.
June 4, 2015); Mathis v. Sec’y of Health & Human Servs., 09-467V, 2014 WL 3955650 (Fed.
Cl. Spec. Mstr. July 24, 2014); McHerron v. Sec'y of Health & Human Servs., 07-753V, 2014
WL 3360324 (Fed. Cl. Spec. Mstr. June 18, 2014); Barnette v. Sec’y of Health & Human Servs.,
06-868V, 2012 WL 5285414 (Fed. Cl. Spec. Mstr. Sept. 26, 2012); aff’d 110 Fed. Cl. 34 (2013);
Deribeaux v. Sec’y of Health & Human Servs., 05-306V, 2011 WL 6935504 (Fed. Cl. Spec.
Mstr. Dec. 9, 2011); aff’d 105 Fed. Cl. 583 (2012); aff’d 717 F. 3d 1363 (Fed. Cir. 2013); Snyder
et al. v. Sec’y of Health & Human Servs., 07-59V, 2011 WL 3022544 (Fed. Cl. Spec. Mstr. May
27, 2011); rev’d 102 Fed. Cl. 305 (2011); reinstated 553 F.App’x. 994 (Fed. Cir. 2014); Harris v.
Sec’y of Health & Human Servs., 07-60V, 2011 WL 2446321 (Fed. Cl. Spec. Mstr. May 27,
2011); rev’d 102 Fed. Cl. 282 (2011); reinstated 553 F. App’x. 994 (Fed. Cl. 2014); Hammitt v.
Sec’y of Health & Human Servs., 07-170V, 2011 WL 1135878 (Fed Cl. Spec. Mstr. March 4,
2011); review denied 98 Fed. Cl. 719 (2011); aff’d 676 F.3d 1373 (Fed. Cir. 2012); Sucher v.
Sec’y of Health & Human Servs., 07-58V, 2010 WL 1370627 (Fed. Cl. Spec. Mstr. March 15,
2010); Stone v. Sec’y of Health & Human Servs., 04-1041V, 2010 WL 1848220 (Fed. Cl. Spec.
Mstr. Apr. 15, 2010); rev’d 95 Fed. Cl. 233 (2010); remanded 2011 WL 836992 (Fed. Cl. Spec.
Mstr. Jan. 20, 2011); review denied 99 Fed. Cl. 187 (2011); aff’d 676 F.3d 1373 (Fed. Cir.
2012); rehearing denied 690 F.3d 1380 (2012); cert. denied 133 S. Ct. 2022 (2013);
Schniegenberg v. Sec’y of Health & Human Servs., 13-347V, 2014 WL 4674382 (Fed. Cl. Spec.
Mstr. Apr. 29, 2014); Craner v. Sec’y of Health & Human Servs., 10-475V, 2011 WL 6401290
(Fed. Cl. Spec. Mstr. Oct. 27, 2011).

2
his first seizure, neither that initial seizure nor his vaccinations caused his Dravet syndrome or
neurological complications. For that reason, the undersigned also finds that respondent has
provided preponderant evidence of an alternative cause of E.O.’s injuries, and, therefore,
petitioners are not entitled to compensation.

I. Procedural History

Petitioners filed a petition on June 25, 2010, alleging that the DTaP, Hep B, IPV, PCV,
and Rotavirus vaccinations that E.O. received on April 9, 2009, caused him to develop “a fever
and febrile seizures . . . [and] a chronic complex partial seizure disorder.” Petition at ¶¶ 5, 6.
Over the next nine months, petitioners filed medical records, and on March 16, 2011, petitioners
filed a statement of completion. See Petitioners’ Exhibits (“Pet’rs’ Exs.”) 1-19; Statement of
Completion dated March 16, 2011. At a status conference on April 6, 2011, respondent
identified additional records related to the genetic testing of E.O. and his parents. See Order
dated April 19, 2011 (ECF No. 29) at 1. Over the next three months, petitioners filed records of
E.O.’s genetic test results, neuropsychological evaluation, occupational and speech evaluations,
Emergency Medical Services (“EMS”) reports, and updated medical records from E.O.’s
pediatric neurologist, Dr. James Wheless. See Pet’rs’ Exs. 20-26 (ECF Nos. 30-31, 34, 39).

On July 29, 2011, respondent filed her Rule 4(c) Report, recommending against
compensation. Resp’s Rep. at 1. Respondent stated that petitioners did not allege that E.O.
suffered an injury listed on the Vaccine Injury Table, nor did they establish causation in fact by a
preponderance of the evidence. Id. at 13. Respondent further noted from E.O.’s medical records
that “he had tested positive for SCN1A gene defect (borderline SMEI syndrome),” 4 and that
“[E.O.’s] own treating neurologist, Dr. Wheless, has attributed [E.O.’s] seizure disorder not to
the vaccines, but to a mutation in his SCN1A gene.” Id. at 10-11, 14 (citing Pet’rs’ Ex. 9 at 37;
Pet’rs’ Ex. 18 at 26, 28).

On April 16, 2012, petitioners filed an expert report from Dr. Yuval Shafrir. See Pet’rs’
Ex. 28. In addition to the expert report, petitioners filed Dr. Shafrir’s curriculum vitae and 17
medical articles referenced in his report. See Pet’rs’ Exs. 29-46. Dr. Shafrir agreed with Dr.
Wheless that E.O.’s condition is “very reminiscent of Dravet syndrome.” See Pet’rs’ Ex. 28 at
11. However, he argued that medical literature has shown an association between Diphtheria-
Tetanus-Pertussis (“DPT”) vaccination and the onset of Dravet syndrome. See id. at 13.

On December 17, 2012, respondent filed expert reports from Dr. Gerald Raymond and
Dr. Rajesh Sachdeo, along with their curricula vitae and medical literature. See Resp’s Exs. A-
D. Dr. Raymond and Dr. Sachdeo both opined that E.O.’s SCN1A gene mutation, rather than the
vaccines, was more likely the cause of his Dravet syndrome. Resp’s Ex. A at 8, 11-12; Resp.’s
Ex. C at 1. On March 14, 2014, and August 8, 2014, petitioners filed two supplemental expert
reports from Dr. Shafrir. Pet’rs’ Exs 47, 68. Respondent filed a supplemental expert report from
Dr. Raymond on September 22, 2014. Resp’s Ex. E.

4
Severe Myoclonic Epilepsy of Infancy (“SMEI”) is also known as Dravet syndrome. See
Section II(C), infra, for a more complete description.

3
 On September 22, 2014, respondent filed a motion for a ruling on the record,
recommending dismissal of the case on the basis of the written record without an evidentiary
hearing. Resp’s Motion for a Ruling on the Record (“Resp’s Mot.”) dated September 22, 2014
(ECF No. 93) at 13. Respondent argued that the claim should be dismissed, because petitioners
failed to distinguish their case from previously dismissed SCN1A cases 5 with the same experts
and medical theory. Id. at 13-14. On December 9, 2014, petitioners filed their third and fourth
supplemental expert reports from Dr. Shafrir, along with additional medical literature. Pet’rs’
Exs 74-80. On the same day, petitioners also filed a response to respondent’s motion, indicating
that E.O.’s case included new evidence that was not presented in the prior SCN1A cases. Pet’rs’
Response to Resp’s Mot. (ECF No. 99) at 2 n.2. Further, petitioners claimed that precluding
them from presenting their theory of causation simply because they used the same expert as prior
SCN1A cases would become a “dangerous precedent.” Id. at 5.

On January 17, 2015, respondent filed a reply to petitioners’ response. See Resp’s Reply
dated January 7, 2015 (“Resp’s Reply”) (ECF No. 101). Respondent clarified that she was not
arguing that petitioners’ theory of causation is precluded. Id. at 1. Rather, respondent reiterated
that petitioners failed to establish causation in fact by preponderant evidence and that the written
record should be adequate for the undersigned to dismiss the case without an evidentiary hearing.
Id. at 1.

During a status conference on March 3, 2015, the undersigned denied respondent’s
motion for a ruling on the record because, at the time, it was unclear whether E.O.’s specific
SCN1A gene mutation was pathogenic. Specifically, his mutation was described as “a variant of
‘unknown significance,’ and [it had not yet] been described in the literature.” Order dated March
3, 2015 (ECF No. 102) at 1. The undersigned sought more information about the mutation and
requested that petitioners submit E.O.’s updated pediatric neurological records, his parents’
genetic testing results, and an evaluation from his genetic specialist. Id. at 2. She also ordered
both parties to submit supplemental expert reports. Id. In accordance with the undersigned’s
March 3, 2015 Order, petitioners filed additional medical records, three supplemental expert
reports from Dr. Shafrir, and medical literature. Pet’rs’ Ex. 81-135. Respondent filed a second
supplemental expert report from Dr. Raymond. Resp’s Ex. F.

On September 22, 2015, after reviewing the additional records and expert reports, the
undersigned held a status conference to discuss her thoughts on the resolution of this case. See
Order dated September 22, 2015 (ECF No. 113). Subsequently, on March 28, 2016, petitioners
filed a motion for a ruling on the record. Pet’rs’ Motion for a Ruling on the Record dated March
28, 2016 (“Pet’rs’ Mot.”) (ECF No. 126). Respondent filed a responsive brief on May 31, 2016.
Resp’s Response to Pet’rs’ Mot. dated May 31, 2016 (“Resp’s Resp.”) (ECF No. 127) at 1. On

5
See Resp’s Mot. at 10-13 (citing Stone v. Sec’y of Health & Human Servs,, 676 F.3d 1373
(Fed. Cir. 2012); Deribeaux v. Sec’y of Health & Human Servs., 717 F.3d 1363 (Fed. Cir. 2013);
Snyder v. Sec’y of Health & Human Servs., 553 F. App’x 994 (Fed. Cir. 2014); Barnette v.
Sec’y of Health & Human Servs., 110 Fed. Cl. 34 (2013); Waters v. Sec’y of Health & Human
Servs., No. 08-76V, 2014 WL 300936 (Fed. Cl. Spec. Mstr. Jan. 7, 2014)).

4
July 15, 2016, petitioners filed a reply to respondent’s response. Pet’rs’ Reply dated July 15,
2016 (ECF No. 128) at 2.

This matter is now ripe for adjudication on petitioners’ motion for a ruling on the record.

II. Summary of Relevant Medical Records and Affidavit

A. Summary of Medical Records

E.O. was born on October 2, 2008, at St. Mary’s Hospital in Athens, Georgia. Pet’rs’ Ex.
16 at 34. He was delivered at 38 weeks of an uncomplicated pregnancy. See generally, Pet’rs’
Exs. 7, 16. His birth weight was six pounds 14 ounces and his APGAR scores 6 were six and
seven at one and five minutes, respectively. See Pet’rs’ Ex. 16 at 34. E.O.’s neonatal course
presented “respiratory distress and decreased pulses in the lower extremities.” Id. at 46. E.O.
was admitted to the special care nursery. Id. His initial condition was stabilized by dextrose
intravenous (“IV”) fluids, antibiotics, and an IV bolus of normal saline. Id. On October 4, 2008,
E.O.’s physical examination was unremarkable except for jaundice, and he was discharged
home. Id. at 47.

E.O. received his early pediatric care from Dr. Melissa Martin and Dr. Jeanne Martin.
See generally, Pet’rs’ Ex. 8. On April 9, 2009, E.O. saw Dr. Jeanne Martin for his six-month
well-baby visit and vaccinations. Id. at 19. His temperature on examination was 97.4 degrees
Fahrenheit. Id. Dr. Jeanne Martin reported that E.O. had normal growth and development as a
six-month infant, despite his puffy right eye with clear drainage. Id. E.O. received DTaP, Hep
B, IPV, PCV, and Rotavirus vaccinations during this visit. Id. at 3.

At approximately 11:30 that evening, Mrs. Oliver awoke to “repetitive grunting sounds
through a baby monitor,” and found E.O. seizing in his bed. Pet’rs’ Ex. 15. She called 911, and
EMS arrived at the Oliver home a few minutes later. Pet’rs’ Ex. 26 at 3. Ms. Oliver stated that
E.O.’s seizure lasted approximately four to five minutes. Id. The EMS caregiver reported that
E.O. was “very sluggish and appear[ed] postictal . . . and [his] skin [was] very hot to [the] touch
on [his] forehead as well as his trunk.” Id. at 6.

At 12:19 a.m. on April 10, 2009, E.O. arrived at the Banks-Jackson-Commerce (“BJC”)
Medical Center. Id. He presented to the ER with “a fever of 101.3 degrees, red eyes with
discharge from his right eye, and a runny nose.” Id. at 5; Pet’rs’ Ex. 1 at 13. E.O.’s parents
reported to the ER physician, Dr. Michael Herron, that E.O. received vaccinations the previous
day. Pet’rs’ Ex. 1 at 13. On examination, Dr. Herron reported that E.O. was “happy, playful,
smiling, and active in the ER.” Id. After reviewing his blood test results and radiology report,
Dr. Herron diagnosed E.O. with a febrile seizure. Id. at 16-19. Dr. Herron prescribed pediatric

6
Appearance, Pulse, Grimace, Activity, and Respiration (“APGAR”) score is a method of
evaluating newborns to determine their overall health. See Nelson Textbook of Pediatrics (19th
ed. 2011) at 536-37.

5
Tylenol and Motrin and discharged E.O. with instructions to follow up with his pediatrician. Id.
at 19.

On April 10, 2009, E.O. was seen by his pediatrician, Dr. Jeanne Martin, for follow-up.
See Pet’rs’ Ex. 8 at 18. Dr. Martin that E.O. was “okay by the time he got to the hospital,” and
that his condition was normal on examination except for a tearing right eye. Id. His body
temperature was stabilized at 97.1 with no fever. Id. Dr. Martin diagnosed E.O. with complex
febrile seizure and conjunctivitis in the right eye. Id.

E.O. did not have any health issues or seizures for the next two months. See Pet’rs’ Ex.
19 at 190, 198. On June 16, 2009, approximately two months after his six-month vaccinations,
Mrs. Oliver noticed that E.O. was not moving his right side and did not interact with her for
about ten minutes. Id. at 192. She took him to the ER of St. Mary’s Hospital. Id. at 190. The
ER nurse, Roberta Walters, reported E.O.’s level of consciousness as “awake and alert.” Id. at
191. The result of his brain CT scan was normal. Id. at 206. The ER physician, Dr. Rick
Brewer, diagnosed E.O. with a “possible seizure” and discharged him in a stable condition. Id.
at 190. Dr. Brewer ordered an EEG 7 test for E.O. and instructed petitioners to follow up with
Dr. Elizabeth Sekul at the Medical College of Georgia (“MCG”). Id. at 196, 202. The EEG
results were “mildly normal for age because of asymmetrical slowing over the left hemisphere.”
Id. at 182. Although nonspecific for E.O.’s age, the EEG specialist concluded that such a finding
“may reflect interictal seizure in the left hemisphere.” Id.

On June 18, 2009, E.O. was seen by Dr. Elizabeth Sekul, a pediatric neurologist at MCG.
Pet’rs’ Ex. 4 at 84-87. On examination, Dr. Sekul described E.O. as “alert, playful, interactive,
very socially engaging . . . [and] in no apparent distress.” Id. at 85. In a response letter to Dr.
Brewer, Dr. Sekul reported that E.O. had “normal development [and] has had two events.” Id. at
86. Dr. Sekul stated that the first event was “associated with his immunization,” and “the second
event was only some transient hemiparesis, most likely secondary to a Todd.” 8 Id. He also
reported that E.O.’s EEG results from St. Mary’s Hospital showed “no epileptiform discharges”
in the left hemisphere and “this would have been consistent with possible Todd’s.” Id. Dr.
Sekul planned to order an MRI to exclude stroke-like changes and a repeat EEG to ensure that
the left hemisphere was normalized. Id. The repeat EEG was normal. Id. After reviewing
E.O.’s medication history of Diastat 2.5 mg, Dr. Sekul prescribed Trileptal and discharged him
home. Id.

7
An electroencephalogram (“EEG”) is a diagnostic test that records “the potentials on the skull
generated by currents emanating spontaneously from nerve cells in the brain,” which “correlate
well with different neurologic conditions.” Dorland’s Illustrated Medical Dictionary
(“Dorland’s”) (32d ed. (2012)) at 602.
8
“Todd’s paralysis is a neurological condition experienced by individuals with epilepsy, in
which an epileptic seizure is followed by hemiparesis or monopoiesis lasting for a few minutes
or hours, or occasionally for several days.” Dorland’s at 1378. Hemiparesis is defined as
“paralysis of the lower half of one side of the body.” Id. at 837. Monopoiesis means
“paresthesia on a single limb.” Id. at 1178.

6
 Over the summer, E.O. had several seizures, all resulting in ER visits. See Pet’rs’ Ex. 19
at 168; Pet’rs’ Ex. 5 at 3; Pet’rs’ Ex. 19 at 153. On August 17, 2009, at approximately 10
months of age, E.O. was evaluated by Dr. Jun Park, a pediatric neurologist in Atlanta, Georgia.
See Pet’rs’ Ex. 2 at 5-6. Dr. Park reported that E.O. had a total of six “sporadic” seizures, with
the first event “at six months of age on the night after the six-month vaccination,” and the last
event on the previous Wednesday. Id. at 5. Dr. Park documented that E.O.’s head CT scan,
brain MRI, EEG, and repeat EEG were reportedly normal. Id. Dr. Park also emphasized that
E.O. had “normal developmental milestones.” Id. Dr. Park diagnosed E.O. with focal epilepsy.
Id. He ordered a repeat EEG, which was normal and showed “no focal features or epileptiform
discharges.” Id. at 2. Dr. Park prescribed Diastat for the first time and instructed petitioners to
follow up in six weeks. Id. at 6.

Beginning in March 2010, E.O. began to have prolonged seizures, all of which resulted in
ER visits. See Pet’rs’ Ex. 3 at 2-8; Pet’rs’ Ex. 4 at 5-6, 15-24, 33-34, 54-56, 71-72. On March 1,
2010, E.O. had a seizure that lasted about three hours, and he was admitted to the pediatric
intensive care unit (“ICU”) at MCG. Pet’rs’ Ex. 4 at 54-70. Dr. Suzanne Strickland diagnosed
him with “complex partial seizures” and prescribed Keppra 250 mg, Trileptal 240 mg, and
Diastat 7.5 mg. Id. at 54-56. During another ER visit on March 8, 2010, Dr. Strickland reported
that E.O. continued to have “daily seizures” and “the episodes have become progressively worse
with increase in duration as well as frequency.” Dr. Strickland updated his prescriptions to
include Keppra 300 mg, Dilantin 25 mg, and Diastat 7.5 mg. Id. at 33-35. On April 9, 2010,
E.O. returned to the ER at MCG after a prolonged seizure that lasted forty-five minutes. Id. at
18. During this episode, Dr. Strickland reported that E.O. did not respond to Diastat. Id. at 16.
E.O. did not become stabilized to baseline until given two doses of Ativan 1 mg. Id. at 3, 24.
Upon discharge, he developed additional seizure activities and required extra doses of Diastat
and Dilantin. Pet’rs’ Ex. 4 at 3. On April 24, 2010, Dr. Park diagnosed E.O. with “intractable
epilepsy from possible left frontal epileptic foci.” Id. at 4. Dr. Park prescribed Keppra 3.5 mL,
Klonopin 0.5 mg, Dilantin 25/25/50 mg, and Diastat 7.5 mg. Id.

On April 26, 2010, E.O. was referred to Dr. James Wheless, a pediatric neurologist at
LeBonheur Children’s Medical Center (“LeBonheur”) in Memphis, Tennessee. See Pet’rs’ Ex. 9
at 2. Dr. Wheless described E.O.’s seizures for the past two months as “characterized by brief
cessation of his ongoing activity or brief pauses, with eye blink.” Id. at 7. Dr. Wheless noted
that E.O. had not adequately responded to Trileptal, Dilantin, Keppra, Klonopin,
Ativan/Lorazepam, Topamax, Depakote, or ethosuximide. Id. at 7, 32. After a full diagnostic
evaluation, Dr. Wheless diagnosed E.O. with “intractable, cryptogenic childhood absence
epilepsy.” Id. at 9. Despite being placed on numerous medications, E.O.’s seizures could not be
controlled. Id. at 7, 32.

On June 1, 2010, E.O. returned to LeBonheur for further diagnostic testing. Pet’rs’ Ex. 9
at 31. He tested positive for SCN1A gene defect. Id. at 36-37. E.O.’s parents also underwent
genetic testing for SCN1A mutation and neither parent had the mutation. See Pet’rs’ Ex. 18 at
26; Pet’rs’ Ex. 23 at 2-8. During E.O.’s stay at the hospital, he had a prolonged seizure that
lasted 50 minutes at the time of admission, but his condition improved after he was placed on a
ketogenic diet. See Pet’rs’ Ex. 9 at 37-38. On June 4, 2010, Dr. Wheless discharged E.O. with
diagnosis of “intractable, symptomatic absence and partial new onset seizures of independent

7
hemisphere origin and episodes of status epilepticus,” and “sodium channelopathy due to
SCN1A gene defect.” Id. at 37. He prescribed Carnitor 1.5 mL, Keppra 500mg, as well as a
ketogenic diet plan with calcium and multivitamin supplements. Id. at 38.

On July 19, 2010, E.O. was seen by Dr. Wheless for follow-up. See Pet’rs’ Ex. 18 at 25-
27. E.O.’s mother reported that he continued to have frequent absence seizures, but that he only
had one prolonged complex partial seizure on June 13, 2010. Id. at 26. E.O.’s developmental
delay became apparent around this time. Id.; see also Resp’s Ex. C at 4. Dr. Wheless performed
a general physical exam, a neurologic exam, and a motor exam. Pet’rs’ Ex. 18 at 26. The
impression was “intractable, symptomatic childhood absence and complex partial seizures of
independent hemisphere origin secondary to SCN1A gene defect (borderline SMEI syndrome),”
and “encephalopathy characterized by speech delay.” Id.

B. Affidavit from E.O.’s Mother

The record includes an affidavit from E.O.’s mother, Laura Oliver. See Pet’rs’ Ex. 15 at
¶ 1. Mrs. Oliver stated that E.O. received his two-, four-, and six-month vaccinations at Dr.
Jeanne Martin’s office. Id. at ¶ 7. She reported that E.O. was healthy and developing normally
prior to receipt of any vaccinations, and he had no noticeable reactions to his two- or four-month
vaccinations except for a slight fever. Id. at ¶¶ 6, 8.

Mrs. Oliver stated that the night E.O. received his six-month vaccinations, she “awoke to
repetitive grunting sounds through a baby monitor,” and found E.O. “unconscious and unable to
wake up.” Id. at ¶ 9. She reported that “[E.O.] was convulsing in his entire body; [his] eyes
rolled back in his head[,] and he turned blue.” Id. Mrs. Oliver stated that her husband called 911
and an ambulance took them to the ER. Id. She reported that E.O.’s vitals dropped and his skin
became blotchy on their way to the ER, which forced them to “make an emergency stop at a
local hospital for immediate care.” Id. She stated that the ambulance took them to the ER of
BJC Medical Center, where E.O. was diagnosed with a febrile seizure. Id.

Mrs. Oliver also described E.O.’s second seizure episode, which resulted in another ER
visit to St. Mary’s Hospital. Id. at ¶ 10. She stated that “[E.O.] was found in his crib not moving
one side of his body, and he had no neck control to hold his head up.” Id. She stated that the ER
physician diagnosed E.O. with Todd’s paralysis as a result of a seizure and that Dr. Elizabeth
Sekul, a pediatric neurologist, diagnosed E.O. with a complex partial seizure disorder. Id.

Mrs. Oliver reported that on March 1, 2010, E.O. had a “prolonged complex partial
seizure of more than three hours,” and was admitted to the ICU of MCG. Id. at ¶ 14. She also
reported E.O.’s several prolonged seizures in June 2010. Id. at ¶ 15. Mrs. Oliver described that
“there is no pattern to the frequency of [E.O.’s] seizures,” and he continues to have “absence
seizures all day long every few seconds.” Id.

Mrs. Oliver stated that despite “more than 25 changes to dosages and medications”
prescribed by MCG pediatric neurologists, E.O.’s seizures remained “uncontrolled in November
2010,” and “continued to worsen.” Id. at ¶¶ 11-12, 17. She reported that the length of his
prolonged complex partial seizures fluctuated from a few seconds to more than three hours. Id.

8
at ¶ 11. In addition to medications, Mrs. Oliver stated that E.O. was administered sedatives
several times during his testing procedures at MCG, including MRI, EEG, video EEG, and
SPECT. 9 Id. at ¶ 12. She further reported that E.O. suffered serious side effects caused by
medications and the strict ketogenic diet plan, including little growth, weight loss, restlessness
during sleep, aggressive behaviors, stomach discomfort, and other problems. Id. at ¶ 19.

Mrs. Oliver’s statement also highlighted the difficult impact of her son’s disease on the
family. Id. at ¶¶ 18, 20-21. She stated that E.O.’s uncontrolled symptoms and the frequent
hospital visits forced her to take a leave from work, which in turn forced the family to seek other
avenues of health insurance that could cover E.O.’s condition. Id. Fearing additional
uncontrolled seizures, Mrs. Oliver described that the family is unable to take E.O. in public, to
children’s functions, or to relatives’ residences where “an appropriate medical facility is not
within a reasonable distance.” Id. at ¶ 20.

C. Genetic Testing, SCN1A Mutation, and Dravet Syndrome

In addition to the facts set forth above, the following facts relate to E.O.’s SCN1A gene
mutation and Dravet syndrome.

1. SCN1A Gene Mutation

On April 26, 2010, Dr. Yong Park at MCG referred E.O. to Dr. James Wheless, a
pediatric neurologist at LeBonheur, for neurologic evaluation and treatment recommendations.
See Pet’rs’ Ex. 9 at 2. Dr. Wheless recommended a full diagnostic evaluation consisting of
prolonged video EEG, brain MRI, SPECT, neuropsychological testing, occupational and speech
assessments, and genetic studies. Id. at 5. On the same day, E.O. underwent genetic testing for
SCN1A mutation. Id. at 31. On June 1, 2010, Athena Diagnosis, Inc. reported E.O.’s genetic
test results, which identified “a DNA sequence variant” on his SCN1A gene. 10 See Pet’rs’ Ex.
20 at 1. The significance of the mutation was characterized as “unclear or unknown.” Id.

On June 4, 2010, Dr. Wheless diagnosed E.O. with “sodium channelopathy due to
SCN1A gene defect,” based upon the results of his genetic testing. See Pet’rs’ Ex. 9 at 37.
Based on the results of the genetic testing, Dr. Wheless recommended a new medication,
Carnitor 1.5 mL, as well as the ketogenic diet plan with calcium and multivitamin supplements.
Id. at 38.

9
The SPECT test is “single-photon emission computed tomography.” Dorland’s at 1742.
10
Athena Diagnosis, Inc. reported E.O.’s test results as follows:
“SCN1A DNA Sequencing Variants:
SCN1A variant 1: 4 base pair deletion;
Nucleotide position: IVS1+4_IVS1+7;
DNA variant type: Variant of unknown significance.
No other abnormal DNA sequence variants were identified in the remainder of the coding
sequence or intron/exon junctions of this gene.” Pet’rs’ Ex. 20 at 1.

9
 E.O.’s parents also underwent genetic testing for SCN1A mutation and the results
revealed that they do not have the mutation. Thus, E.O.’s mutation is de novo. See Pet’rs’ Ex.
18 at 26; Pet’rs’ Ex. 23 at 2-8.

The SCN1A gene encodes for a sodium channel, which is “a portion of a channel that
allows the transport of sodium molecules across cell membranes in the neurons.” Resp’s Ex. A
at 6-7. The flow of sodium molecules permits appropriate transmission of information from one
cell to another. Id. at 6. SCN1A gene mutations affect neuron cells in various ways, depending
on the particular mutation, and how the mutation affects the structure and function of the sodium
channel. Id. So far, several neurological conditions have been associated with the SCN1A gene
mutation, including familial hemiplegic migraines, several epilepsy syndromes, Generalized
Epilepsy with Febrile Seizures plus (“GEFS+”), and E.O.’s condition, Dravet syndrome. Id. at
5-7.

There are several SCN1A databases reported in the literature. One is maintained by the
Institute of Neuroscience at GuangZhou Medical University in Guangdong Province in China
Pet’rs’ Ex. 100 at 1 (citing database at http://www.gzneurosci.com/scn1adatabase/index.php)
(last visited Jan. 23, 2017). “In this database, there [is a] mutation…which appears identical to
the mutation of E.O.” Id.; see also database entry No. 40. The child with the identical mutation
was also reported to have Dravet syndrome. Resp’s Ex. F at 2.

2. Dravet Syndrome

Dr. Wheless first diagnosed E.O. with borderline severe myoclonic epilepsy of infancy
(“SMEI”) syndrome in March 2010, when he was 21 months old. Pet’rs’ Ex. 18 at 26. The
diagnosis was based on the fact that E.O. showed signs of encephalopathy which were
characterized by his speech delay. Id. At the time of diagnosis, it was also noted that E.O.
suffered from “intractable, symptomatic childhood absence and complex partial seizures of
independent hemisphere origin.” Id. All of these symptoms are indicators of Dravet syndrome.

Dravet syndrome is an extremely rare syndrome with an incidence of one in 40,000
children. Pet’rs’ Ex. 28 at 12; Pet’rs’ Ex. 35 at 488. 11 Seventy to 80 percent of Dravet syndrome
cases are caused by SCN1A mutations. Pet’rs’ Ex. 35 at 488. Ninety percent of these mutations
are de novo. 12 Id. The gene which is affected by the mutation is in the alpha subunit of the
SCN1A gene, which “encodes the voltage-dependent sodium channel (Nav 1.1).” Pet’rs’ Ex. 64

11
See Berkovic, Samuel, et al., “De-novo Mutations of the Sodium Channel Gene SCN1A in
Alleged Vaccine Encephalopathy: A Retrospective Study,” 5 LANCET NEUROL. 488-492 (2006)
[Pet’rs’ Ex. 35].
12
In this context, a de novo mutation means “an alteration in a gene that is present for the first
time in one family member as a result of a mutation in a germ cell (egg or sperm) of one of the
parents or in the parents or in the fertilized egg itself.” National Institutes of Health, “Genetics
Home Reference,” available at (last visited
Dec. 8, 2016).

10
at 1. 13 The SCN1A gene is “an important epilepsy-related sodium channel gene.” Pet’rs’ Ex. 48
at 9. 14 Research has shown that there is a “powerful network hyperexcitability underlying
Dravet syndrome, a severe epilepsy of infancy.” Id.

Dravet syndrome is also referred to as SMEI and is an epilepsy syndrome that starts at
about six months of age. Pet’rs’ Ex. 40 at 3. 15 The initial seizure may be accompanied by a
fever. Id. Development is generally normal at the onset of the disease, but a subsequent and
progressive decline in intellectual function often occurs. Id. The time frame in which the
disease first presents overlaps with the schedule of routine childhood vaccinations. Id. at 2-3.
Children with Dravet syndrome usually have clonic 16 seizures in the first year of life, followed
by myoclonic 17 seizures. Pet’rs’ Ex. 37 at 1. In addition to developmental delay, the children
may have an ataxic 18 gait. Id. 19 The seizures are refractory to treatment. Id.

The clinical course of Dravet syndrome is “characterized by onset of recurrent febrile
and/or afebrile hemiclonic or generalized seizures…. in a previously healthy infant.” Pet’rs. Ex.
41 at 2. 20 The seizures usually evolve into multiple types of seizures which are drug resistant.
Id. By the second year of life, children usually have an encephalopathy with cognitive,
behavioral and developmental delays. Id.; Pet’rs’ Ex. 55 at 2. 21 Even children with Dravet

13
Okumura, Akihisa, et al., “Acute Encephalopathy in Children with Dravet Syndrome,” 53
EPILEPSIA 79-86 (2012) [Pet’rs’ Ex. 64].
14
Klassen, Tara, et al., “Exome Sequencing of Ion Channel Genes Reveals Complex Profiles
Confounding Personal Risk Assessment in Epilepsy,” 145 CELL 1036-48 (2011) [Pet’rs’ Ex. 48].
15
Tro-Baumann, Blanca, et al., “A Retrospective Study of the Relation Between Vaccination and
Occurrence of Seizures in Dravet Syndrome, 52 EPILEPSIA 175-78 (2011) [Pet’rs’ Ex. 40].
16
Clonic is an adjective of the word “clonus,” which is defined as “alternate muscular
contraction and relaxation in rapid succession.” Dorland’s at 373.
17
Myoclonic seizures are characterized by “shock-like contractions of a portion of a muscle, an
entire muscle, or a group of muscles, restricted to one area of the body or appearing
synchronously or asynchronously in several areas.” Dorland’s at 1222.
18
Ataxia is the “failure of muscular coordination; irregularity of muscular action.” Dorland’s at
170.
19
Guerrini, Renzo, & Oguni, Hirokazu, “Borderline Dravet Syndrome: A Useful Diagnostic
Category,” 52 EPILEPSIA 10-12 (2011) [Pet’rs’ Ex. 37].
20
Catarino, Claudia, et al., “Dravet Syndrome as Epileptic Encephalopathy: Evidence from
Long-Term Course and Neuropathology,” 134 BRAIN 2982-3010 (2011) [Pet’rs’ Ex. 41].
21
Brunklaus, Andreas, et al., “Prognostic, Clinical and Demographic Features in SCN1A
Mutation-Positive Dravet Syndrome,” 135 BRAIN 2329-36 (2012) [Pet’rs’ Ex. 55].

11
syndrome who have well controlled epilepsy experience developmental problems. Pet’rs’ Ex. 55
at 4.

III. Standards for Adjudication

The Vaccine Act was established to compensate vaccine-related injuries and deaths. §
300aa-10(a). “Congress designed the Vaccine Program to supplement the state law civil tort
system as a simple, fair and expeditious means for compensating vaccine-related injured persons.
The Program was established to award ‘vaccine-injured persons quickly, easily, and with
certainty and generosity.’” Rooks v. Sec’y of Health & Human Servs., 35 Fed. Cl. 1, 7 (1996)
(quoting H.R. Rep. No. 908 at 3, reprinted in 1986 U.S.C.C.A.N. at 6287, 6344).

This Court is given jurisdiction to award compensation for claims where the medical
records or medical opinion have demonstrated causation in fact by a preponderance of the
evidence. See §§ 300aa-13(a)(1) and 11(c)(1)(C)(ii)(I). The preponderance standard requires a
petitioner to demonstrate that it is more likely than not that the vaccine at issue caused the injury.
Moberly v. Sec’y of Health & Human Servs., 592 F.3d 1315, 1322 n.2 (Fed. Cir. 2010). Proof of
medical certainty is not required. Bunting v. Sec’y of Health & Human Servs., 931 F.2d 867,
873 (Fed. Cir. 1991). In particular, a petitioner must prove that that the vaccine was “not only
[the] but-for cause of the injury but also a substantial factor in bringing about the injury.”
Moberly, 592 F.3d at 1321 (quoting Shyface v. Sec’y of Health & Human Servs., 165 F.3d 1344,
1352-53 (Fed. Cir. 1999)); Pafford v. Sec’y of Health & Human Servs., 451 F.3d 1352, 1355
(Fed. Cir. 2006). A petitioner who satisfies this burden is entitled to compensation unless
respondent can prove, by a preponderance of the evidence, that the vaccine’s injury is “due to
factors unrelated to the administration of the vaccine.” § 300aa-13(a)(1)(B).

To receive compensation under the Program, petitioners must show either: (1) that E.O.
suffered a “Table Injury”—i.e., an injury listed on the Vaccine Injury Table—corresponding to a
vaccine that he received, or (2) that E.O. suffered an injury that was actually caused by the
vaccine (or vaccines) he received. See §§ 300aa-13(a)(1)(A) and 11(c)(1); Capizzano v. Sec’y of
Health & Human Servs., 440 F.3d 1317, 1319-20 (Fed. Cir. 2006).

Because petitioners do not allege that E.O. suffered a Table injury, they must prove that a
vaccine E.O. received caused his injury. To do so, petitioners must demonstrate, by
preponderant evidence: (1) a medical theory causally connecting a vaccine and E.O.’s injury
(“Althen Prong One”); (2) a logical sequence of cause and effect showing that a vaccine was the
reason for his injury (“Althen Prong Two”); and (3) a showing of a proximate temporal
relationship between a vaccine and his injury (“Althen Prong Three”). § 300aa-13(a)(1); Althen,
418 F.3d at 1278.

The causation theory must relate to the injury alleged. Thus, petitioners must provide a
reputable medical or scientific explanation that pertains specifically to this case, although the
explanation need only be “legally probable, not medically or scientifically certain.” Knudsen v.
Sec’y of Health & Human Servs., 35 F.3d 543, 548-49 (Fed. Cir. 1994). Petitioners cannot
establish entitlement to compensation based solely on their assertions. Rather, a vaccine claim
must be supported either by medical records or by the opinion of a medical doctor. § 300aa-

12
13(a)(1). In determining whether petitioners are entitled to compensation, the undersigned shall
consider all material contained in the record, § 300aa-13(b)(1), including “any . . . conclusion,
[or] medical judgment . . . which is contained in the record regarding . . . causation.” § 300aa-
13(b)(1)(A). The undersigned must weigh the submitted evidence and the testimony of the
parties’ offered experts and rule in petitioners’ favor when the evidence weighs in their favor.
See Moberly, 592 F.3d at 1325-26 (holding that factfinders are expected and entitled to
determine the reliability of the evidence presented to them and the credibility of the persons
presenting that evidence”); Althen, 418 F.3d at 1280 (holding that “close calls” should be
resolved in petitioner’s favor).

Another important aspect of the causation-in-fact case law under the Program concerns
the factors that a special master should consider in evaluating the reliability of expert testimony
and other scientific evidence relating to causation issues. In Daubert v. Merrell Dow Pharm.,
Inc., 509 U.S. 579 (1993), the Supreme Court listed certain factors that federal trial courts should
utilize in evaluating proposed expert testimony concerning scientific issues. In Terran v. Sec’y
of Health & Human Servs., 195 F.3d 1302, 1302 (Fed. Cir. 1999), the Federal Circuit ruled that
it is appropriate for special masters to utilize the Daubert standard as a framework for evaluating
the reliability of causation-in-fact theories presented in Program cases.

IV. Issues to be Decided

As an initial matter, both parties agree that E.O. was born with a mutation of his SCN1A
gene. Pet’rs’ Memorandum (“Memo”) dated March 28, 2016 (ECF No. 126) at ¶ 9; Resp’s
Resp. at 4-5. Thus, the parties agree that the vaccines did not cause the genetic mutation. See
Pet’rs’ Memo at ¶ 9. Rather, the parties dispute whether E.O.’s April 9, 2009 vaccinations can
and did cause his seizure disorder, Dravet Syndrome, and resulting neurological condition. See
Petition at ¶ 6; see also Pet’rs’ Memo at ¶¶ 4, 34-35, 50. Secondly, the parties dispute whether
E.O.’s vaccinations caused a significant aggravation of his condition. See Pet’rs’ Memo at ¶ 56.

V. Expert Qualifications

In support of their claims, petitioners offer seven reports by Dr. Yuval Shafrir. See
Pet’rs’ Exs. 28, 47, 68, 74, 86, 100, 102. Respondent provides three reports by Dr. Gerald
Raymond and one report by Dr. Rajesh Sachdeo. See Resp’s Exs. A, C, E-F.

1. Petitioners’ Expert, Dr. Yuval Shafrir

Dr. Yuval Shafrir is a pediatric neurologist at Sinai Hospital in Baltimore, Maryland.
Pet’rs’ Ex. 46 at 3. He attended Tel Aviv University Sackler School of Medicine in Israel during
1976-1982 and conducted his pediatric residency rotations in Israel. Id. at 1. After moving to
the United States, he completed a pediatric residency at Cornell University Medical College. Id.
Afterwards, Dr. Shafrir completed a fellowship in pediatric neurology at Washington University
Medical Center in St. Louis and a second fellowship in pediatric neurophysiology and
epileptology at Miami Children’s Hospital. Id. Dr. Shafrir is board-certified in neurology with a
specialty in pediatric neurology, clinical neurophysiology, and epilepsy. Id. at 2. In addition to
his active private practice in pediatric neurology, Dr. Shafrir also served as an Assistant

13
Professor in Neurology and Pediatrics at multiple academic and medical institutions, including
United Services University of the Health Sciences, Georgetown University School of Medicine,
the University of Oklahoma School of Medicine, and most recently, the University of Maryland
School of Medicine. Id. at 2-3. He has conducted numerous clinical studies in pediatric
neurology and has published more than 20 peer-reviewed articles and abstracts. Id. at 3-6. Since
1991, he has been frequently invited to attend grand rounds and lectures across the country, as
well as national and international academic annual meetings of pediatric neurology. Id. at 6-8.

2. Respondent’s Expert, Dr. Gerald Raymond

Dr. Gerald Raymond is a pediatric neurologist who specializes in neuropathology and
genetics. Resp’s Ex. B at 1. He attended the University of Connecticut School of Medicine from
1980-1984. Id. After medical school, Dr. Raymond completed residency rotations in pediatrics
and neurology at the Johns Hopkins Hospital and the Massachusetts General Hospital. Id. He
then completed a fellowship in developmental neuropathology at Université Catholique de
Louvain in Brussels, Belgium, and a second fellowship in genetics and teratology at Harvard
University School of Medicine. Id. Dr. Raymond is board-certified in pediatrics, clinical
genetics, and neurology, with special competency in child neurology. Id. He has had extensive
clinical, instructional, and research experience in the fields of neurology, pediatrics, and
genetics. See id. at 1-2, 9-10. He has peer reviewed and published numerous articles in these
fields. See id. at 2-9. Dr. Raymond joined the University of Minnesota Medical Center in
January 2013. Id. at 1. Since then, he has been working as a Professor and Physician of
Pediatric Neurology in the Department of Neurology. Id.

3. Respondent’s Expert, Dr. Rajesh Sachdeo

Dr. Rajesh Sachdeo is a neurologist who specializes in epilepsy. Resp.’s Ex. D at 1. He
attended medical school at the Christian Medical College in Ludhiana, India. Id. After moving
to the United States, Dr. Sachdeo completed his residency at Loyola University Medical Center
in Maywood, Illinois. Id. He obtained his subspecialty training in epilepsy through a fellowship
program at Rush-Presbyterian St. Luke’s Medical Center in Chicago, Illinois. Id. at 2.
Currently, Dr. Sachdeo is a Clinical Professor of Neurology at Rutgers University Robert Wood
Johnson Medical School (formerly known as “University of Medicine and Dentistry of New
Jersey”) in New Brunswick, New Jersey. Resp’s Ex. C at 1. He also serves as an attending
physician at a number of hospitals, including the Robert Wood Johnson University Hospital,
Princeton University Medical Center, and the Jersey Shore Medical Center. Id. He has been
board-certified in neurology and neurophysiology since 1982. Id. Dr. Sachdeo has served on
many committees and received a Humanitarian Award from the New Jersey Epilepsy
Foundation. Id. He is active in clinical research and has conducted more than 50 studies on
epilepsy. Id. Dr. Sachdeo has authored book chapters and more than 40 articles. Id. He is
familiar with the standard of neurological care in the United States and has an active clinical
practice of pediatric epilepsy. Id. Particularly, Dr. Sachdeo has seen and treated approximately
50 patients with Dravet syndrome. Id.

14
 VI. Analysis

The undersigned evaluates petitioners’ medical theory below. The undersigned has
reviewed and considered all of the evidence in this case and the entire record as a whole. The
following is by no means a complete recitation of all of the relevant facts and evidence
considered. See §300aa-13(a) (stating that the special master should consider the “record as a
whole”).

A. Althen Prong One: Reliable Medical Theory

Under Althen Prong One, petitioners must set forth a medical theory explaining how the
vaccines could have caused E.O.’s injury. Andreu v. Sec’y of Health & Human Servs., 569 F.3d
1367, 1375 (Fed. Cir. 2009); Pafford, 451 F.3d at 1355-56. This prong requires petitioners to
make an evidentiary showing that the vaccines E.O. received on April 9, 2009, “can” cause his
alleged injury. Id. at 1356.

Petitioners’ theory of causation need not to be medically or scientifically certain;
however, it must be informed by a “sound and reliable medical or scientific explanation.”
Knudsen, 35 F.3d at 548; see also Veryzer v. Sec’y of Health & Human Servs., 98 Fed. Cl. 214,
223 (2011) (noting that special masters are bound by both § 300aa-13(b)(1) and Vaccine Rule
8(b)(1) to consider only evidence that is both “relevant” and “reliable”). If petitioners rely upon
a medical opinion to support their theory, the basis for the opinion and the reliability of that basis
must be considered in the determination of how much weight to afford the offered opinion. See
Broekelschen v. Sec’y of Health & Human Servs., 618 F.3d 1339, 1347 (Fed. Cir. 2010) (noting
that the special master’s decision is often “based on the credibility of the experts and the relative
persuasiveness of their competing theories.”); Perreira v. Sec’y of Health & Human Servs., 33
F.3d 1375, 1377 n.6 (Fed. Cir. 1994) (holding that an “expert opinion is no better than the
soundness of the reasons supporting it.”) (citing Fehrs v. United States, 620 F.2d 255, 265 (Ct.
Cl. 1980)).

a. Petitioner’s First Proposed Mechanism: “Second Hit” Theory

Petitioners’ expert, Dr. Shafrir, agrees that the SCN1A mutation is a necessary cause of
Dravet syndrome, but he opines that the mutation alone is not sufficient to cause the disease.
Pet’rs’ Ex. 74 at 2. He proposes two alternative mechanisms whereby the vaccinations could
have caused E.O.’s Dravet syndrome. Pet’rs’ Ex. 68 at 5; Pet’rs’ Ex. 102 at 8. The first
proposed theory is that E.O.’s vaccinations may have been a “second hit.” Pet’rs’ Ex. 47 at 8.
Dr. Shafrir cites Klassen et al., 22 explaining that for many diseases, including cancer, it has “been
hypothesized that the appearance and severity of the disorder are a simple result of the net
accumulation of genetic variants or ‘hits’ in a disease pathway, where crossing an undefined risk
threshold divides affected from unaffected individuals.” Pet’rs’ Ex. 47 at 3 (quoting Pet’rs’ Ex.
48 at 1036). Dr. Shafrir further opines that “the occurrence of a single seizure, which here, was
clearly induced by vaccination, make[s] the brain more prone to seizures from other causes.” Id.

22
Klassen, et al., 145 CELL 1036.

15
at 8. Dr. Shafrir concludes that a “single seizure can cause dramatic changes in gene expression
in the brain, which may serve as the second hit mentioned by Klassen.” Id.

Dr. Shafrir also described the “second hit” mechanism as a “gene-environment
interaction.” See Pet’rs’ Ex. 28 at 16. He states that the abnormal gene is the “first hit,” but he
does not believe that the mutation alone would trigger Dravet syndrome without “an
environmental effect (vaccination) that temporally shifts the age at onset.” Id. at 16. Dr. Shafrir
concedes that his second hit theory is “a new [and] very complex field of research,” and studies
in this particular area are still at “a very preliminary stage.” Pet’rs’ Ex. 47 at 8. Likewise, Dr.
Shafrir acknowledges that studies to support this theory have not been performed in “Dravet
syndrome or its animal mode[l].” Id.

Klassen, however, does not provide support for Dr. Shafrir’s theory. In Klassen, 23
researchers performed exome sequencing of 237 ion channel subunit genes looking for exonic
variations in 139 healthy controls and 142 persons with idiopathic epilepsy (“IE”) and developed
ion channel genomic profiles. In doing so, they found “remarkable genetic complexity and
overlapping patterns of both rare and common variants in known excitability disease genes,” in
both the control and IE groups, “indicating that the potential for clinical expression of these
common disorders is embedded in the fabric of all human genomes.” Pet’rs’ Ex. 48 at 1037.

Klassen used the phrases “two-hit” and “third-hit” to describe hypotheses derived from
complex computational modeling of different genetic variations for the purpose of examining
two different theories, the “load hypothesis” and the “single-cell” model. The load hypothesis
suggests that “if IE is the result of accumulating mutations of small effect in known disease
genes, then the “load” or summation of those deleterious mutations will surpass some liability
threshold contributing to the overt excitability phenotype.” Id. Pet’rs’ Ex. 48 at 1038.

Klassen made three important findings, “[F]irst[,] that the architecture of ion channel
variation …consists of dense and highly complex patterns of common and rare alleles; second,
that structural variants in…epilepsy genes appear in otherwise healthy individuals; and third, that
individuals with epilepsy typically carry more than one mutation in known [] epilepsy genes.”
Pet’rs’ Ex. 48 at 1037. In conclusion, “[P]henotypic variation in epilepsy…may arise from a
diverse array of channel alleles at a single focus, or a constellation of novel alleles in related or
distant subunit genes.” Id. So while Klassen suggests that mutations may combine to cause
disease, the study did not examine vaccines or other environmental factors or draw conclusions
about the theories proposed by Dr. Shafrir.

b. Petitioners’ Second Proposed Mechanism: Immune-Mediated
Response

23
A full discussion of Klassen is far beyond the scope of this decision, but it appears that one of
the goals of the research was to predict phenotypes using bioinformatics for the purpose of
developing drugs to more effectively treat epilepsies. See Pet’rs’ Ex. 48 at 1043.

16
 Dr. Shafrir’s second proposed mechanism is based on an immune-mediated response to
the DTaP vaccination. One of his suggested immune responses is the mechanism of molecular
mimicry. Pet’rs’ Ex. 68 at 5; Pet’rs’ Memo at 18. Dr. Shafrir opines that “components of the
DTap vaccination contain multiple areas of homology with multiple brain proteins, including
multiple ion channels in epilepsy related genes.” Pet’rs’ Ex. 102 at 5. Dr. Shafrir cites studies
by Kanduc 24 in support of this theory. Kanduc’s work, however, lacks persuasive authority
because it dealt with potassium channel proteins, not sodium channel proteins, which are at issue
here. See Pet’rs’ Ex. 113. Moreover, when Kanduc studied the diphtheria toxin, he did not
examine epilepsy-related genes. See Pet’rs’ Ex. 102 at 6. Thus, Kanduc’s findings do not
support the existence of homology given the facts and circumstances of this case.

Dr. Shafrir also cites Obergon, 25 a study that deals with antibodies found in children with
autism. According to Dr. Shafrir, in Obergon’s study, autistic children were found to have
antibodies to epitopes of the CASpr2 protein, which has been reported to have homology with
part of the pertussis vaccine. See Pet’rs’ Ex. 68 at 6. Petitioners hypothesize that children with
SCN1A mutations have immune abnormalities that cause them to develop autoantibodies to the
CASpr2 protein through the mechanism of molecular mimicry. Pet’rs’ Memo at 20. According
to petitioners’ theory, CASpr2 is homologous to pertussis filamentous hemagglutinin, which is
found in the TDaP vaccine. Id. at 20-21. Antibodies against CASpr2 may affect the potassium
channel and cause an imbalance between excitation and inhibition in the brain’s neuronal
circuits, resulting in seizures. Id. at 21. Dr. Shafrir attempts to analogize the findings of the
Obergon study to the facts here. But this case involves epilepsy and Dravet syndrome in
children with an SCN1A mutation, and not autism, thus the analogy does not hold. Dr. Shafrir
also recognized the limitations in the Obergon study when he stated, “It is important to
remember that such a level of demonstration (referencing the Obergon study) of actual molecular
mimicry with brain component [has] not been achieved with most immunizations.” Pet’rs’ Ex.
75 at 2.

Dr. Shafrir similarly opined that several different components of the DTaP vaccination
are homologous with human proteins associated with epilepsy. Pet’rs’ Ex. 102 at 5. He cites to
studies, Lucchese et al., 26 and Bavaro et al., 27 to support this opinion. However, these studies

24
Kanduc, D., “Peptide Cross-Reactivity: the Original Sin of Vaccines,” S4 FRONTIERS IN
BIOSCIENCE 1393-401 (2012) [Pet’rs’ Ex. 112]; see also Pet’rs’ Ex. 113.
25
Obergon, Demian, et al., “Potential Autoepitope Within the Extracellular Region of Contactin-
Associated Protein-Like 2 in Mice,” 4 BRITISH J. MED. & RESEARCH 416-432 [Pet’rs’ Exs. 76,
116].
26
Lucchese, Guglielmo, et al., “The Peptide Network Between Tetanus Toxin and Human
Proteins Associated with Epilepsy,” 2014 EPILEPSY RESEARCH AND TREATMENT 1-12 (2014)
[Pet’rs’ Ex. 113].
27
Bavaro, Simona Lucia, et al., “Pentapeptide Sharing Between Corynebacterium Diphtheria
Toxin and the Human Neural Protein Network,” 33 IMMUNOPHARMACOLOGY AND
IMMUNOTOXICOLOGY 360-72 (2011) [Pet’rs’ Ex. 114].

17
were based on highly theoretical data, and the protein sequences were obtained from resources
“built on information extracted from the studies on molecular biology of disease candidate genes
with in-depth annotations of their function at the protein level derived from the current scientific
literature.” Pet’rs’ Ex. 114 at 361. The authors of these two articles raise many interesting
questions which require further study, but reach no conclusions as to whether the vaccines here
share homology with epilepsy-related proteins.

In further support of their hypothesis, petitioners cite a study by Lilleker et al. 28wherein
researchers tested seizure patients for the presence of voltage-gated potassium channel complex
antibodies (“VGKC Abs”), as well as other antibodies associated with epilepsy, and treated them
with immunotherapy accordingly. Pet’rs’ Ex. 77 at 776. The team reported that a patient with
autoantibodies against CASpr2 stopped having seizures after undergoing immunosuppressive
therapy. Id. at 777. Presumably, petitioners cite the Lilleker study to suggest that molecular
mimicry occurred between the DTaP vaccine and CASpr2 because a patient with antibodies to
CASPr2 responded to immunotherapy. This presumption, however, is overly simplistic, as
Lilleker looked primarily at antibodies against the voltage-gated potassium channel complex,
rather than the sodium channel, which is at issue here. Moreover, the researchers looked
specifically at adult patients who had been newly diagnosed with unexplained epilepsy, and they
did not make their results applicable to children with the condition or children with Dravet
syndrome. Id. at 776.

Dr. Shafrir also relies on the works of Catarino 29 and McIntosh 30 for the position that
Dravet syndrome is an immune mediated condition caused in part by vaccines. Pet’rs’ Ex. 68 at
5. The authors of the McIntosh 31 study found that DTaP vaccination “triggered a significantly
earlier onset of seizures,” in patients with SCN1A mutations. See Pet’rs’ Ex. 28 at 15. In the
study, patients were divided into two groups, one that had seizures within two days of
vaccination (“vaccination-proximate”), and the other group that had seizures not temporally
associated with vaccine administration (“vaccination-distant”). Id.; Pet’rs’ Ex. 36 at 6. The
mean age of the child for seizure onset was “18.4 weeks in the vaccination-proximate group and
26.2 weeks in the vaccination-distant group.” Id. The onset difference between the two groups
was approximately eight weeks. Id. Based on the difference in onset, Dr. Shafrir opined that a
vaccine “alters the course of seizures in children with SCN1A gene mutation.” See Pet’rs’ Ex.
28 at 14.

28
Lilleker, James, et al., “VGKC Complex Antibodies in Epilepsy: Diagnostic Yield and
Therapeutic Implications,” 22 SEIZURE 776-79 (2013) [Pet’rs’ Ex. 77].
29
Catarino, C.B., et al., “Dravet Syndrome as Epileptic Encephalopathy: Evidence From Long
Term Course and Neuropathology,” 134 BRAIN 2982-3010 (2011) [Pet’rs’ Ex. 41].

McIntosh, Anne M., et al, “Effects of Vaccination on Onset and Outcome of Dravet Syndrome:
30

A Retrospective Study,” 9 LANCET NEUROL. 592-98 (2010) [Pet’rs’ Ex. 36].
31
McIntosh et al., 9 LANCET NEUROL. 592.

18
 Although he relied on the McIntosh study, Dr. Shafrir disagreed with its conclusion that
there was “no difference between the two groups, vaccination-proximate and vaccination-
distant,” with regard to “intellectual disability,” or “occurrence regression.” Id. at 14-15. The
McIntosh study, however, does not support Dr. Shafrir’s theory because the results of the study
show that children with Dravet syndrome experience regression and developmental delays
regardless of whether they receive vaccinations. 32 Id. Similarly, the Catarino article does not
support Dr. Shafrir’s theory because the study found that 70 to 80 percent of adult patients with
Dravet syndrome have an SCN1A mutation, and 90 percent of these mutations are de novo. 33

Another article cited by Dr. Shafrir was authored by Black and Waxman, 34 who
questioned whether those who have the SCN1A mutation have “some abnormalities in their
immune function, in addition to abnormalities in the electrical activities in the brain.” Pet’rs’ Ex.
68 at 5. But Dr. Shafrir concedes that whether this “abnormality affects the response of the
affected infants to the DTP or DTap vaccination is [] unknown.” Id.

Respondent’s expert, Dr. Raymond, disagreed with Dr. Shafrir’s proposed theories and
opined that the SCN1A mutation is the cause of E.O.’s Dravet syndrome. He explained that the
SCN1A mutation affects neurons in the central nervous system. Resp’s Ex. A at 6. Neuron cells
maintain “an electrical potential or gradient” across cell membranes and deliver information
signals with changes in the electrical potential. Id. The SCN1A gene “encodes a portion of a
channel” that controls the flow and transport of sodium molecules across cell membranes in the
neurons. Id. at 7. The sodium pores in the membranes serve as a “voltage responsive switch.”
Id. When the voltage meets a certain level, the pores allow passage of sodium ions from one side
of the membranes to another. Id. The genetic abnormality that causes Dravet syndrome is a
mutation of the “voltage-gated Na+ channel subunit.” Id. at 4. Thus, the mutation prevents the
normal flow and transport of sodium molecules of neuron cells. SCN1A mutations have been
associated with a variety of seizure disorders, including generalized epilepsy with GEFS+ and
Dravet syndrome. Id. at 7. Specifically, “a relatively high percentage” of SCN1A mutations

32
For a more detailed discussion of the McIntosh article, see infra p. 21. The undersigned also
agrees with Snyder’s similar reasoning regarding the McIntosh article. See Snyder, 2011 WL
3022544, at *23.
33
For a more detailed discussion of the Catarino article see infra p. 25.
34
Black, Joel A., & Waxman, Stephen G., “Sodium Channels and Microglial Function,” 234
EXPERIMENTAL NEUROLOGY 302-15 (2012) [Pet’rs’ Ex. 66].

19
have been found in patients diagnosed with Dravet syndrome. Id. at 4. Dr. Raymond cited
works of Claes 35, 36 and Mulley37 to support his opinion.

Claes et al. studied the DNA and SCN1A gene in seven patients with SMEI. Resp’s Ex.
A2 at 1327. The researchers found a heterozygous 38 mutation in the SCN1A gene of each of the
seven patients which their parents did not have (de novo). Id. at 1329. Six of the seven patients
had either a splice-site or nonsense mutation. Id. Claes et al. further observed that “in the
majority of patients with SMEI, the mutation results in early termination of translation of the
protein, thereby producing a C-truncated SCN1A protein ...” Id. at 1330. A later study by Claes
et al. analyzed the mutations in the SCN1A gene of nine additional patients with Dravet
syndrome. Resp’s Ex. A7 at 615. As before, the researchers found that all mutations occurred
de novo, with six missense, two nonsense, and one splice donor site mutation. Id. at 618.
Similarly, Mulley et al. found that “the overwhelming majority of known mutations in SCN1A
lead to severe myoclonic epilepsy of infancy…” Resp’s Ex. A8 at 535. They further note that
“[t]he percentage of SMEI patients carrying SCN1A mutations varies between 33 and 100
[percent]…. The majority of these mutations are novel changes.” Id. at 537-38.

In essence, Dr. Raymond disagreed with Dr. Shafrir’s proposed theories of second hit and
immune-mediation/molecular memory, stating that the SCN1A mutation is the “sole cause” of
E.O.’s Dravet syndrome. Id. at 1; see Resp’s Ex. A at 13. The basis for Dr. Raymond’s opinion
is three-fold. First, the existing medical studies and literature have established that a significant
alteration in the SCN1A gene alone is sufficient to cause Dravet syndrome. See Resp’s Ex. E at
3-4. In contrast, Dr. Shafrir relied on studies that were not specific to SCN1A, or retrospective
studies with methodology problems. 39 Id. Second, animal models have demonstrated significant
abnormalities of SCN1A mutation that “mirror the human condition,” and in these studies the
animals spontaneously developed seizures without any triggers. Id. Third, the McIntosh et al. 40

35
Claes, Lieve, et al., “De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe
Myoclonic Epilepsy of Infancy,” 68 AM. J. HUM. GENET. 1327-32 (2001) [Resp’s Ex. A2].
36
Claes, Lieve, et al., “De Novo SCN1A Mutations Are a Major Cause of Severe Myoclonic
Epilepsy of Infancy,” 21 HUMAN MUTATION 615-21 (2003) [Resp’s Ex. A7].
37
Mulley, John C., et al., “SCN1A Mutations and Epilepsy,” 25 HUMAN MUTATION 535-42
(2005) [Resp’s Ex. A8].
38
Heterozygosity is defined as “the state of possessing pairs of different alleles at one or more
loci.” Dorland’s at 857.
39
For example, some of the studies cited by Dr. Shafrir did not accurately document fever events
for all the patients.
40
Pet’rs’ Ex. 36; see also Resp’s Ex. A24.

20
and Berkovic et al. 41 studies show that the occurrence of febrile seizures following vaccinations
does not change the clinical course or outcome of Dravet syndrome. See Resp’s Ex. A at 11.

In the McIntosh et al. study, children with SCN1A mutations in the vaccination-
proximate group had “the same genetic alternations” as those in the vaccination-distant group,
and the clinical outcomes of the two groups were not significantly different. See Resp’s Ex. E at
4; Resp’s Ex. A at 12. Although the authors of the McIntosh 42 study found that DTaP
vaccination triggered a significantly earlier onset of seizures in patients with SCN1A mutations,
they concluded that children who had seizure onset within two days after vaccination, versus
those that did not have seizures temporally associated with vaccine administration, experienced
the same outcome of disability and regression. Pet’rs’ Ex. 36 at 6.

Berkovic et al. had similar findings. In Berkovic, the authors performed a retrospective
study of 14 patients who had a seizure within 72 hours of receiving the pertussis vaccination and
who allegedly had vaccine encephalopathy. Pet’rs’ Ex. 35 at 488. All 14 patients showed
“severe epilepsy with multiple seizure types and intellectual disability,” and eight of the 14
patients had SMEI. Id. at 489. Eleven patients had mutations in the SCN1A gene. Id. at 488.
Berkovic cited four reasons why it was unlikely that the pertussis vaccination played a
significant role in vaccine encephalopathy: first, although vaccinations can trigger seizures,
“there is no evidence of long-term adverse outcomes[;]” second, more than half of the patients
were afebrile when they had their first seizure, suggesting that fever is not essential; third, the
neuroimaging data did not reveal evidence of “an inflammatory or destructive process[;]” and
finally, missense mutations and truncation reported in “conserved parts of SCN1A” were not
observed in hundreds of healthy controls. Id. at 491. Berkovic concludes that, “[I]ndividuals
with [SCN1A] mutations seem to develop SMEI … whether or not they are immunized in the
first year of life. We do not think that avoiding vaccination … would prevent onset of this
devastating disorder in patients who already harbor the SCN1A mutation.” Id.

Animal models have played an “extremely important” role in understanding the
pathogenesis of Dravet syndrome. Resp’s Ex. A at 7. One of these studies was described by
Oakley. 43 Oakley’s group studied mice that were created with an abnormal deletion of one copy
of the SCN1A gene. Resp’s Ex. A9 at 3. At birth, the mice appeared normal, but their
conditions changed as they aged. Id. One group of mice was subject to hyperthermia, or
increased temperature, until seizures were provoked. Id. The other group was not exposed to
temperature elevations. Id. The latter group of mice subsequently developed seizures even
though they were not exposed to elevated temperatures. Id. Young mice initially had only

41
Berkovic, Samuel, et al., “De Novo Mutations of the Sodium Channel Gene SCN1A in
Alleged Vaccine Encephalopathy: A Retrospective Study,” 5 LANCET NEUROL. 488-92 (2006)
[Pet’rs’ Ex. 35].
42
McIntosh et al., 9 LANCET NEUROL. 592.
43
Oakley, John C., “Temperature- and Age-Dependent Seizures in a Mouse Model of Severe
Myoclonic Epilepsy in Infancy,” 106 PNAS 3994-99 (2009) [Resp’s Ex. A9].

21
febrile seizures, but as they aged, they spontaneously developed generalized and myoclonic
seizures. Resp’s Ex. A at 3-4. The mice developed seizure disorders without “any bacterial,
viral, or immune altering agent or precipitant, including immunizations.” Id. at 8. Thus, the
animal studies show that there is no need to invoke environmental factors to explain seizure
onset in the face of the SCN1A mutation. Id. at 9. Of particular interest to Dr. Raymond is the
fact that the mice had conditions typically seen in Dravet syndrome in humans, including gait
problems and behavioral abnormalities. Id. at 7. He concluded that the mouse model
“recapitulates the human disease with surprising fidelity.” Id. at 8.

c. Evaluation of the Evidence

Althen Prong One requires petitioners to set forth a reliable medical theory explaining
how the vaccines E.O. received could have caused his alleged injury. Althen, 418 F.3d at 1278.
While scientific certainty is not required to establish causation under the Act, the theory must be
supported by a “sound and reliable” medical or scientific explanation. Id. at 1279; Knudsen, 35
F.3d at 548.

Here, the undersigned finds that petitioners have failed to provide preponderant evidence
to support their medical theory. Dr. Shafrir did not provide a “sound and reliable” medical
theory to explain how the vaccinations at issue cause Dravet syndrome. Although he proposed
two theories of causation, second hit and immune-mediation, his opinions were not as persuasive
as those of Dr. Raymond. In addition, none of the articles cited by Dr. Shafrir suggest that
vaccines can cause Dravet syndrome or change the clinical course of Dravet syndrome, and
several come to the opposite conclusion. While some studies demonstrate an association
between vaccination and fever, and thus the onset of seizures in children with Dravet syndrome,
the existing medical literature has established that vaccination does not affect the clinical course
or prognosis of Dravet syndrome. The animal models, as presented by Dr. Raymond, provide
strong evidence that Dravet syndrome will develop in children with the SCNIA mutation,
whether or not they receive vaccinations.

B. Althen Prong Two: Logical Sequence of Cause and Effect

Under Althen Prong Two, petitioners must prove by a preponderance of the evidence that
there is a “logical sequence of cause and effect showing that the vaccination was the reason” for
E.O.’s injury. Capizzano, 440 F.3d at 1324 (quoting Althen, 418 F.3d at 1278). “Petitioner[s]
must show that the vaccine was the ‘but-for’ cause of the harm . . . or in other words, that the
vaccine was the ‘reason for the injury.’” Pafford, 451 F.3d at 1356. This requires petitioners to
show that the vaccines E.O. received on April 9, 2009, actually caused the alleged injury. See
Pafford, 451 F.3d at 1354. However, petitioners are not required to make a specific type of
evidentiary showing. See Capizzano, 440 F.3d at 1325. That is, petitioners are not required to
offer “epidemiologic studies, rechallenge, the presence of pathological markers or genetic
disposition, or general acceptance in the scientific or medical communities to establish a logical
sequence of cause and effect.” Id. Instead, petitioners may satisfy their burden by presenting
circumstantial evidence and reliable medical opinions. Id. at 1325-26.

22
 Dr. Shafrir agrees that E.O. has the splice site mutation in his SCN1A gene and that
E.O.’s clinical course is “very reminiscent of” Dravet syndrome. See Pet’rs’ Ex. 28 at 11-12.
However, Dr. Shafrir opined that E.O.’s risk of developing the syndrome was “dramatically
increased” by his DTP vaccination. Id. at 12. He stated that the vaccines E.O. received on April
9, 2009, were a “significant factor” in causing his seizure disorder, encephalopathy, and
subsequent injuries. Id. at 20. However, Dr. Shafrir concedes that even if E.O. had not received
the vaccines, he could still have developed Dravet syndrome. Pet’rs Ex. 74 at 3.

Dr. Shafrir calculated the relative risks of the onset of Dravet syndrome following
vaccination and attempted to generalize the theoretical statistics to E.O.’s specific case. Pet’rs’
Ex. 28 at 13-16. His calculation was generated from the data provided in the Nieto-Barrera 44
article. Id. Dr. Shafrir reported that children who received the DPT vaccine had a 17.9 percent
relative risk of experiencing their first seizure within 24 hours of vaccination. Id. at 13. Dr.
Shafrir also noted that McIntosh reported an increased risk of seizure within 48 hours of the
DTaP/DTP vaccine. Id. at 14 (referencing Pet’rs’ Ex. 36). Dr. Shafrir highlighted McIntosh’s
discussion that vaccination may “trigge[r] the onset of Dravet syndrome, causing a temporal
shift,” but he attempted to refute the authors’ main conclusion that vaccination does not affect
the clinical course or outcome of Dravet syndrome, stating that the author misinterpreted the
results due to the small sample size. Id. at 15-16 (referencing Pet’rs’ Ex. 36).

Dr. Shafrir further disagreed that E.O.’s seizure onset was triggered by fever. See Pet’rs’
Ex. 102 at 5. He explained that in the McIntosh study, only 33 percent of the vaccination-
proximate patients had a fever at the onset of seizure. 45 Id.; Pet’rs’ Ex. 28 at 14. He also cited
the Zamponi et al. 46 study to eliminate the theory of fever mechanism. See Pet’rs’ Ex. 54. Dr.
Raymond opined that children with Dravet syndrome, including E.O., generally have their first
seizure after febrile events. 47 Resp’s Ex. E at 3. He cited the Nieto-Barrera 48 article to support
this proposition. According to Nieto-Barrera, among children diagnosed with Dravet syndrome,
the percentage of first seizure cases after any dose of DTP vaccination and the percentage of first
seizure cases in conjunction with fever (not associated with vaccination) are equally high.
Pet’rs’ Ex. 34 at 620

44
See Nieto-Barrera, M., et al., “Severe Myoclonic Epilepsy in Infancy: An Analytical
Epidemiological Study,” 30 REV. NEUROL. 620-24 (2000) [Pet’rs’ Ex. 34].
45
In the McIntosh study, 12 out of 40 children had seizure onset either on the day of vaccination
(n=5) or within 24 hours post-vaccination (n=7) and thus were defined as “vaccination-
proximate” group. Only a third of the vaccination-proximate children (n=4) had a fever, defined
as 100.4 degrees Fahrenheit or above. See Pet’rs’ Ex. 36 at 594.
46
Zamponi, Nelia, et al., “Vaccination and occurrence of seizures in SCN1A mutation-positive
patients: a multicenter Italian study,” 50 PEDIATRIC NEUROL. 228-32 (2014) [Pet’rs’ Ex. 54].
47
On the evening of his six-month vaccinations, E.O. presented to the ER of BJC Medical
Center with a fever of 101.3 degrees Fahrenheit. Pet’rs’ Ex. 1 at 13.

48
Nieto-Barrera, M., et al., 30 REV. NEUROL. 620.

23
 Dr. Raymond opined that E.O.’s Dravet syndrome was not caused or aggravated by any
of the vaccines that he received on April 9, 2009. Resp’s Ex. A at 13. E.O.’s SCN1A mutations
are “splice site mutations,” or more specifically, a deletion of four base pairs in the intronic
region that cause unstable mRNA and lack of protein. Id. at 8. see also Pet’rs’ Ex. 48. 49 Dr.
Raymond explained that splicing defects like E.O.’s are a common cause of human genetic
disorders and a cause of Dravet syndrome. Id. Dr. Shafrir agreed that “splice site mutations may
be associated with absence of the entire nucleotide following exon in the final messenger RNA.”
Ex. 28 at 11. And essentially, Dr. Shafrir agreed with Dr. Raymond’s interpretation of the
genetic tests results that E.O.’s SCN1A mutation “affects an intron (non-coding area of a gene),”
and probably plays a major role in his condition. Pet’rs’ Ex. 74 at 4.

In his initial expert report, Dr. Shafrir stated that the only realistic way to determine
whether E.O.’s specific mutation had an adverse effect was to find another patient with the same
mutation, who had the same disease. Pet’rs’ Ex. 28 at 11. Subsequently, E.O.’s mutation
(IVS1+4_IVS1+7) was reported in another child who has Dravet syndrome. Resp’s Ex. F2. In
2011, Zuberi et al. 50 published a retrospective analysis of genetic and clinical data in 273 persons
with SCN1A mutations to determine how the “nature of a SCN1A mutation may influence the
epilepsy phenotype.” Resp’s Ex. F2 at 594. Twenty four patients (nine percent) had splice site
mutations, which is the type of mutation found in E.O. Id. at 595. In reviewing supplemental
data provided by the authors, Dr. Raymond identified another person with E.O.’s mutation.
Resp’s Ex. F at 2. “[P]atient 11 had an intronic deletion of [four] base pairs.” 51 Id. The
mutation was subsequently added to an SCN1A database published by Meng et al. 52 The child
with E.O.’s mutation was also described as having Dravet syndrome. Id.

Dr. Raymond further refuted Dr. Shafrir’s opinion that the vaccinations caused E.O.’s
Dravet syndrome by criticizing Dr. Shafrir’s reliance on certain medical articles. See Resp’s Ex.

49
Klassen et al. note, “Splice site mutations are implicated in channel disease due to dropout of
exons from the coding messenger RNA (mRNA).” Pet’rs’ Ex. 48 at 1038. The researchers
describe these mutations as functionally severe. Id.
50
See Zuberi, S.M., et al., “Genotype-Phenotype Associations in SCN1A-related Epilepsies,” 76
NEUROLOGY 594-600 (2011) [Resp’s Ex. F2].
51
Zuberi reports the mutation as c.264+3del4 and list it in the SCN1A mutation database as
IVS1+4_IVS1+7(2), which is the same mutation as E.O. Resp’s Ex F at 2 (referencing Resp’s
Ex. F2). In reviewing the article’s supplemental data, Dr. Raymond noted, “patient 11 had an
intronic deletion of 4 base pairs. They report this as c.264+3del4. This was subsequently listed
in a new SCN1A mutation database as IVS1+4_IVS1+7(2). The only information that the
authors provide is that this child had classical Dravet syndrome (Dravet-C).” Resp’s Ex. F at 2
(internal citations omitted).
52
Meng, H., et al., “The SCN1A Mutation Database: Updating Information and Analysis of the
Relationships Among Genotype, Functional Alteration, and Phenotype,” 36 HUM. MUTAT. 573-
80 (2015) [Resp’s Ex. F1].

24
A at 10-13. Dr. Shafrir cited the Nieto-Barrera study to calculate relative risks for immunization
and its relationship with seizure onset. Ex. 28 at 13-16 (citing Pet’rs’ Ex. 34). Dr. Raymond
noted that this article was published before genetic diagnostic methods of Dravet syndrome
became available. Resp’s Ex. A at 10. Without actual data of gene positive rates in that study
cohort, any conclusions based on the study are flawed. Id. at 10.

Dr. Shafrir cited the works of Catarino 53 and Jozwiak 54 to support his opinions, but Dr.
Raymond found the results of these two studies irrelevant and inapplicable to E.O.’s case.
Resp’s Ex. A at 12 (referencing Pet’rs’ Exs. 41-42). Catarino et al. studied 22 adult patients with
with Dravet syndrome, finding that 70 to 80 percent of Dravet syndrome cases occur due to
SCN1A mutations, of which 90 percent occur de novo. Pet’rs’ Ex. 41 at 2982-83. However, the
goal of the study was to analyze Dravet syndrome in adult patients, in part to measure the long
term course of the disease and determine “whether Dravet syndrome could [] be considered an
epileptic encephalopathy later in life.” Id. at 2984. As Dr. Raymond stated, “there is nothing in
this report that demonstrates a role of environmental factors in the pathogenesis of Dravet
syndrome.” Resp’s Ex. A at 12. The Jozwiak study, on the other hand, discussed seizure onset
among infants with tuberous sclerosis, not Dravet syndrome. Pet’rs’ Ex. 42. Dr. Raymond
believed this study lacked “relevance to the disorders secondary to SCN1A mutations.” Resp’s
Ex. A at 12.

Respondent’s expert, Dr. Sachdeo, opined that E.O’s clinical course and outcome are
consistent with the expected course of Dravet syndrome. Resp’s Ex. C. Based on E.O.’s
medical records, Dr. Sachdeo described that E.O.’s seizures were resistant to any antiepileptic
drugs and he exhibited symptoms of speech delay by 21 months. Id. at 4. E.O.’s vaccinations
did not affect the natural clinical course or outcome of his Dravet syndrome. Id. at 5-6. He also
clarified that while the SCN1A mutation might confer a “seizure susceptibility” to fever
associated with vaccinations, the vaccinations did not trigger E.O.’s underlying genetic disorder.
Id. at 5.

Dr. Sachdeo also noted the presence of primary generalized absence epilepsy on E.O.’s
EEG results. Resp’s Ex. C at 5. E.O.’s EEG results provided support for a genetic basis, as
absence seizures 55 are “usually inherited with a susceptibility locus being described nearby the
SCN1A gene.” Id. Dr. Sachdeo cited the Consortium 56 article to support this proposition.

53
Catarino, et al., 134 BRAIN 2982.
54
Jozwiak, Sergiusz, et al., “Antiepileptic Treatment Before the Onset of Seizures Reduces
Epilepsy Severity and Risk of Mental Retardation in Infants with Tuberous Sclerosis Complex,”
XXX EUROPEAN J. PAEDIATRIC NEUROLOGY 1-8 (2011) [Pet’rs’ Ex. 42].
55
Absence seizures consist of “a sudden momentary break in consciousness of thought or
activity, sometimes accompanied by automatisms or clonic movements, especially of the
eyelids.” Dorland’s at 1688.
56
EPICURE Consortium, et al., “Genome-Wide Association Analysis of Genetic Generalized
Epilepsies Implicates Susceptibility Loci at 1q43, 2p16.1, 2q22.3 and 17q21.32,” 21 HUM. MOL.
GENET. 5359-72 (2012) [Resp’s Ex. C6].

25
Consortium et al. conducted a genome-wide association study 57 on 3020 patients with genetic
generalized epilepsies and a control group of 3954 epilepsy-free participants. Resp’s Ex. C6 at
5361, 5367. This well-controlled study suggests that there is an association between generalized
epilepsy syndrome and a loci nearby SCN1A gene. Resp’s Ex. C6 at 5376. Based on this
finding and the existing literature, Consortium et al. concluded that SCN1A mutation is a
“genetic risk factor” for a wide spectrum of common epilepsy syndromes, including generalized
epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome. Id.

Moreover, Dr. Sachdeo noted from E.O.’s medical records that his seizures did not
respond adequately to medications and his speech delay became apparent by 21 months. Resp’s
Ex. C at 2-4. Dr. Sachdeo stated that E.O.’s drug resistance and developmental delay are
consistent with the clinical course and outcome described by Charlotte Dravet, 58 the pediatric
neurologist who first discovered this disease. Id. at 5. Dr. Sachdeo believed that E.O.’s
condition was not affected by his vaccination, stating that “[E.O.’s] seizures would be drug
resistant and his outcome [would] not change,” even if he had not received vaccinations. Id. He
cited the McIntosh study to support this opinion. Id. at 5 (citing Resp’s Ex. A24). As stated
earlier, in the McIntosh study, the seizure onset occurred 7.8 weeks earlier in the vaccination-
proximate group; however, there were no other statistically significant differences between the
two groups regarding subsequent seizure types, intellectual function, or prognosis. Id. at 5;
Resp’s Ex. A24 at 596.

Dr. Raymond explained why E.O.’s vaccinations did not cause his Dravet syndrome. He
stated:

Reviewing the clinical features in this case, [E.O.] is a child who at the age of [six]
months had a brief febrile seizure without encephalopathy following his immunization.
He subsequently developed multiple seizure types which were medically refractory. He
continued to have sensitivity to elevations in temperature. [At approximately] two years
of age, he manifested developmental issues including language delays and ataxia. His
onset and course are consistent with his diagnosis of Dravet syndrome. Through genetic
testing, he was determined to have a de novo alteration in the SCN1A gene that is
predicted to result in alterations in splicing and therefore protein formation. This
mutation has now been reported in another child with classical Dravet syndrome. Resp’s
Ex. F at 2.

a. Evaluation of the Evidence

57
Genome-wide association studies have been considered as a “powerful and effective
approach” to identify susceptibility genes in complex human diseases. See Resp’s Ex C6 at
5361.
58
Dravet, C., and Bureau, M., Severe myoclonic Epilepsy in Infancy (Dravet Syndrome). In
Engle, J., Petdley, T., Epilepsy: A Comprehensive Textbook, 2nd Ed., Philadelphia: Lippincott
Williams & Wilkins, pp. 2323-28 (2008) [Resp’s Ex. C5].

26
 Althen Prong Two requires preponderant evidence of a “logical sequence of cause and
effect showing that the vaccination was the reason for the injury.” Althen, 418 F.3d at 1278.
This prong is sometimes referred to as the “did it cause” test; i.e., in petitioners’ case, the
question is whether the vaccine (or vaccines) caused the alleged injury. Broekelschen, 618 F.3d
at 1345 (“Because causation is relative to the injury, a petitioner must provide a reputable
medical or scientific explanation that pertains specifically to the petitioner’s case . . . .”); Pafford,
415 F.3d at 3.

Here, the undersigned finds petitioners failed to prove by a preponderance of the
evidence a logical sequence of cause and effect showing that the vaccines E.O. received caused
his Dravet syndrome. Although Dr. Shafrir relied on the McIntosh article to demonstrate his
argument that the vaccinations may have triggered earlier seizures, he ignored the essence of the
McIntosh study that neither vaccines nor time of seizure onset changes the clinical course or
outcome in children with Dravet syndrome.

Moreover, as Dr. Raymond discussed in his expert report, Dr. Shafrir’s attempts to
demonstrate that vaccination causes Dravet syndrome are not persuasive. Dr. Shafrir’s
calculations of the relative risks for immunization were based on an article that lacked accurate
data of gene positive rates, and he cited articles that were not relevant to E.O.’s situation.

In addition, E.O.’s medical records do not support evidence of cause and effect.
Although E.O.’s treating physicians and EMS caregivers reported that his initial seizure was
temporally associated with vaccinations, none of them attributed his development of Dravet
syndrome to the vaccines. Rather, Dr. James Wheless, E.O.’s pediatric neurologist, first
diagnosed him with complex partial seizures “secondary to SCN1A gene defect” at the age of 21
months. Pet’rs’ Ex. 18 at 26.

Further, the splice site mutation identified in E.O.’s SCN1A gene, as explained by Dr.
Raymond, is associated with the dysfunction of the voltage-gated sodium channel, and causally
associated with Dravet syndrome. Resp’s Ex. A at 3, 8. Dr. Raymond explained that splicing
defects are common causes of genetic diseases, including Dravet syndrome. A child with the
same SCN1A mutation as E.O. who also has Dravet syndrome has been reported in a SCN1A
database. The finding of the same mutation in a child with the same illness is very persuasive
evidence that the SCN1A mutation is the cause of E.O.’s Dravet syndrome.

C. Althen Prong Three: Proximate Temporal Relationship

Under Althen Prong Three, petitioners must establish that E.O.’s injury occurred within a
time frame that is medically acceptable for the alleged mechanism of harm. See Pafford, 451
F.3d at 1358 (noting that evidence demonstrating petitioner’s injury occurred within a medically
acceptable time frame bolsters a link between the injury and the vaccination under the ‘but-for’
prong of the causation analysis). Petitioners may satisfy this prong by producing preponderant
proof that the onset of E.O.’s seizures “occurred within a timeframe for which, given the
understanding of the disorder’s etiology, it is medically acceptable to infer causation-in-fact.”
See de Bazan v. Sec’y of Health & Human Servs., 539 F.3d, 1347, 1352 (Fed. Cir. 2008); see
also Faoro, 2016 WL 675491, at *31.

27
 Petitioners may meet their burden by showing: (1) when the injury for which they seek
compensation first appeared after vaccination; and (2) whether the period of symptom onset is
“medically acceptable to infer causation.” See Shapiro v. Sec’y of Health & Human Servs., No.
99-552V, 2011 WL 1897650, at *13 (Fed. Cl. Spec. Mstr. Apr. 27, 2011), aff’d in relevant part
and vacated on other grounds, 101 Fed. Cl. 532, 536 (2011), aff’d, 503 F. App’x 953 (2013) (per
curiam); see also Faoro, 2016 WL 675491, at *31. The acceptable temporal association will vary
according to the particular medical theory advanced in the case. Pafford, 451 F.3d at 1358. A
temporal relationship between a vaccine and an injury, standing alone, does not constitute
preponderant evidence of vaccine causation. See, e.g., Veryzer v. Sec’y of Health & Human
Servs., 100 Fed. Cl. 344, 356 (2011) (explaining that “a temporal relationship alone will not
demonstrate the requisite causal link and that petitioner must posit a medical theory causally
connecting vaccine and injury”), aff’d sub nom. Veryzer v. United States, 475 F. App’x 765
(Fed. Cir. 2012); see also Grant v. Sec’y of Health & Human Servs., 956 F.2d 1144, 1148 (Fed.
Cir. 1992) (holding “a proximate temporal association alone does not suffice to show a causal
link between the vaccination and the injury”).

All of the experts agree that E.O. had his initial seizure on April 9, 2009, the same day he
received vaccines, but they disagree as to the significance of this fact. Dr. Shafrir opined that the
DPT vaccine given to a child with Dravet syndrome creates a “12-fold higher risk” of the child
having seizures within 48 hours, indicating a “tight medically appropriate temporal association
between the vaccination and the onset of seizures,” in those with the SCN1A mutation. Pet’rs’
Ex. 47 at 9. Dr. Shafrir also opined that the vaccines triggered the onset of E.O.’s Dravet
syndrome and the “initial presentation of [E.O.’s] epileptic encephalopathy.” 59 Id.; Pet’rs’ Ex.
28 at 11.

Dr. Raymond disagreed with Dr. Shafrir’s conclusion that E.O.’s first seizure on April 9,
2009, marked the onset of his encephalopathy. Resp’s Ex. A at 9. After his initial seizure on
April 9, 2009, E.O. recovered and returned to baseline, and he did not show evidence of any
injury that was temporally associated with the vaccines. Id. E.O.’s encephalopathy did not
manifest until later, at approximately 21 months of age, which “is consistent with the temporal
profile of [Dravet syndrome] and not to an adverse event subsequent to a brief seizure following
immunization.” Id.

Dr. Raymond also disagreed that the temporal relationship between the vaccines and the
first seizure should be explained as “precipitating the disease.” See Resp’s Ex. A at 10.
Although E.O. had “brief febrile seizure[s],” within 24 hours of his six-month immunizations,
after his initial seizure, he returned to baseline and did not experience further seizures for over
two months.
a. Evaluation of the Evidence

59
Dr. Shafrir concedes that E.O.’s initial presentation of illness did not meet the definition of
encephalopathy as defined by the Vaccine Act. See Pet’rs’ Ex. 28 at 12.

28
 The medical records show, and all of the experts agree, that E.O’s initial seizure, or
seizure onset, was within 24 hours of his six-month vaccinations. While the proximity between
vaccination and seizure onset might suggest a causal relationship between the two events, E.O.
did not develop Dravet syndrome until approximately 21 months of age, more than a year after
these vaccinations. Without evidence of a causal mechanism or evidence of injury, the temporal
relationship between the vaccination and the first seizure alone is not sufficient to establish a
causal link. See Veryzer, 100 Fed. Cl. at 356; see also Grant, 956 F.2d at 1148. Thus, the
undersigned finds that petitioners have failed to meet their preponderant burden under Althen
Prong Three.

D. Standards for Adjudication - Significant Aggravation

The second issue presented by the parties is whether E.O.’s vaccinations significantly
aggravated his pre-existing injury. Pet’rs’ Memo at ¶ 56. The undersigned holds that it did not.

The elements of an off-Table significant aggravation case are set forth in Loving v. Sec’y
of Health & Human Servs., 86 Fed. Cl. 135 (2009); see also W.C. v. Sec’y of Health & Human
Servs., 704 F.3d 1352, 1357 (Fed. Cir. 2013) (holding that “the Loving case provides the correct
framework for evaluating off-Table significant aggravation claims”). There, the Court combined
the Althen test, which defines off-Table causation cases, with a test from Whitecotton v. Sec’y of
Health & Human Servs., 17 F.3d 374 (Fed. Cir. 1994), rev’d on other grounds sub nom., Shalala
v. Whitecotton, 514 U.S. 268 (1995), which concerns Table significant aggravation cases.

The resultant test has six components, which are: (1) the person’s condition prior to
administration of the vaccine, (2) the person’s current condition (or the condition following the
vaccination if that is also pertinent), (3) whether the person’s current condition constitutes a
‘significant aggravation’ of the person’s condition prior to vaccination, (4) a medical theory
causally connecting such a significant worsened condition to the vaccination, (5) a logical
sequence of cause and effect showing that the vaccination was the reason for the significant
aggravation, and (6) a showing of a proximate temporal relationship between the vaccination and
the significant aggravation. Loving, 86 Fed. Cl. at 144.

E. Significant Aggravation Theory

(1) Loving Prong 1: What was E.O.’s Condition Prior to Administration of
the Vaccine?

The first step in the Loving test is to determine E.O.’s condition before he received the
vaccinations at issue. E.O. was born with a mutation of his SCN1A gene. Loving, 86 Fed. Cl. at
144. The specific mutation here is a “splice site” mutation that affects the function of the
protein. Resp’s Ex. A at 8. Mutations of this type are associated with Dravet syndrome. Id.
Although E.O. was born with the SCN1A mutation, his physical and neurological examinations
were all normal prior to his April 9, 2009 vaccinations. Pet’rs’ Ex. 28 at 11. He was healthy and
did not have any seizures prior to the vaccinations.
(2) Loving Prong 2: What is E.O.’s Current Condition (or His Condition
Following the Vaccination, if Also Pertinent)?

29
 The second part of the Loving test is to discuss “the person’s current condition (or
condition following the vaccination if that is also pertinent).” 86 Fed. Cl. at 144. Here, the
condition following E.O.’s vaccinations is most pertinent.

After the initial febrile seizure on April 9, 2009, E.O. returned to baseline, did not exhibit
symptoms of encephalopathy, and he did not have any other seizures until June 16, 2009. Pet’rs’
Ex. 19 at 190-92. Upon admission to the hospital on June 16, 2009, he was afebrile, awake,
alert, and no distress was noted. Id. at 191. On June 18, 2009, E.O. saw Dr. Sekul at MCG, who
noted that his development was normal. Pet’rs’ Ex. 4 at 85. On August 17, 2009, E.O.’s CT
scan, EEG, repeat EEG, and brain MRI were all normal. Pet’rs’ Ex. 2 at 5-6. On September 16,
2009, at 11 months old, his development was still considered normal. See Pet’rs’ Ex. 19 at 168.

Over the next six months, E.O. began to experience prolonged seizures, and on March 1,
2010, he was admitted to the ICU at MCG. Pet’rs’ Ex. 4 at 54-70. Although he was prescribed a
variety of medications, his seizures could not be controlled. Pet’rs’ Ex. 9 at 7, 32. On June 1,
2010, E.O. tested positive for the SCN1A mutation. Id. at 36-37. After he was placed on a
ketogenic diet, some improvement was noted. Id. at 37-38. E.O.’s developmental delay became
apparent at 21 months. Pet’rs’ Ex. 18 at 26; Resp’s Ex. C at 4. On July 19, 2010, Dr. Wheless
performed a neurologic exam on E.O. and diagnosed him with “encephalopathy characterized by
speech delay.” Pet’rs’ Ex. 18 at 25-26.

In summary, E.O. was “completely normal prior to the onset of the seizures and
continued to be normal through the second year of life …. His initial EEG was normal. His
MRIs were normal...” Ex. 28 at 11. He progressively developed multiple types of seizures, and
atypical absences seizures. Id. “Similar to other patients with Dravet syndrome, he is very
sensitive to fever.” Id. The evidence in the record indicates and all of the experts agree that
E.O.’s current condition is consistent with that of a child who has the SCN1A gene mutation and
Dravet syndrome. Ex. 28 at 11.

(3) Loving Prong 3: Does E.O.’s Current Condition (or Condition After
Vaccination) Constitute a “Significant Aggravation” of his Condition
Prior to Vaccination?

The next prong of the Loving test is to determine whether there is a “significant
aggravation” of E.O.’s condition by comparing his condition before vaccination to his condition
after vaccination. The statute defines “significant aggravation” as “any change for the worse in a
preexisting condition which results in markedly greater disability, pain, or illness accompanied
by substantial deterioration in health.” § 300aa-33(4). Based upon the facts as set forth above,
E.O. had a seizure after his April 9, 2009 vaccinations but returned to baseline condition after
that seizure. Subsequently, as Dr. Shafrir notes, E.O. “showed dramatic recovery even after
prolonged seizures,” and after having a seizure at age ten months was described as laughing,
smiling, and very active. Pet’rs’ Ex. 28 at 10. Dr. Shafrir continues, “[v]ery unfortunately,
towards the end of the second year of [his] life, there seemed to be a progressive slowing in
[E.O.’s] development.” Id. “On formal testing, at 21 months, his receptive language was

30
normal, but his expressive language was significantly delayed.” Id. Over time, E.O.’s condition
deteriorated and he developed severe epilepsy and developmental delay.

The undersigned must first make clear that there is no question that E.O.’s condition after
his April 9, 2009 vaccinations changed and over time became worse. However, the question
relevant to this factor of the Loving analysis is whether E.O.’s vaccination significantly
aggravated his Dravet syndrome. In other words, is E.O.’s clinical course and outcome any
different than it would have been if he had not been vaccinated? See Locane v. Sec’y of Health
& Human Servs., No. 99-599V, 2011 WL 3855486, *10-11 (Fed. Cl. Spec. Mstr. Feb. 17, 2011),
aff’d, 99 Fed. Cl. 715 (Fed. Cl. 2011), aff’d, 685 F.3d 1375 (Fed. Cir. 2012) (affirming the
special master’s finding that petitioner’s condition was not inconsistent with the disease
generally and not affected by the vaccinations).

Dr. Shafrir suggests that if E.O. had not received the vaccines on April 9, 2009, the onset
of his Dravet syndrome would have been later, his developmental delay may have been less
severe, or that he may not have developed an illness at all. Pet’rs’ Ex. 28 at 14; Pet’rs’ Ex. 47 at
5, 8; Pet’rs’ Ex. 74 at 3. All of these arguments fail, however, because Dr. Shafrir concedes that
there is no way to predict what E.O.’s outcome would have been if he had not received the
vaccines. Pet’rs’ Ex. 74 at 3; Pet’rs’ Ex. 102 at 4. And Dr. Shafrir concedes that E.O.’s clinical
course is “very reminiscent of” Dravet syndrome. Pet. Ex. 28 at 13. Simply stating what “may”
have happened is a matter of speculation and does not provide petitioners with preponderant
evidence to support their theory.

Moreover, Dr. Shafrir’s opinion that earlier onset of seizures changes the clinical course
of children with Dravet syndrome contradicts the conclusion of the McIntosh study, which found
that although vaccination might appear to trigger the onset of Dravet syndrome, there was no
difference in the clinical outcome in patients with vaccination-proximate seizures. Pet’rs’ Ex. 36
at 6.

Petitioners have failed to show by a preponderance of the evidence that the vaccinations
significantly aggravated E.O.’s condition. He was born with the SCN1A mutation and his
clinical course developed consistently with that condition. The undersigned finds that the
vaccinations did not change his clinical course and thus did not significantly aggravate his
preexisting condition. See Snyder v. Sec’y of Health & Human Servs., 553 F. App’x. 994 (Fed.
Cir. 2014) (holding that the special master was not arbitrary in finding that petitioners’ expert
failed to show that the child’s outcome would have been different had he not received the
vaccinations at issue.)

(4) Loving Prong 4: Is there a Medical Theory Causally Connecting Such a
Significantly Worsened Condition to the Vaccination?

As set forth above, petitioners failed to establish by preponderant evidence a medical
theory causally connecting E.O.’s condition, or any significant aggravation. Therefore,
petitioners also fail to prove a theory as to significant aggravation.

31
 (5) Loving Prong 5: Is there a Logical Sequence of Cause and Effect Showing
that the Vaccination Significantly Aggravated E.O.’s Condition?

For the same reasons set forth in section VI above, petitioners failed to prove by
preponderant evidence a logical sequence of cause and effect showing that the vaccination
significantly aggravated E.O.’s condition.

(6) Loving Prong 6: What is a Proximate Temporal Relationship Between the
Vaccination and the Significant Aggravation?

The last element in the six-part Loving test has origins in Prong III of Althen. As stated
in Loving, this element is “a showing of a proximate temporal relationship between vaccination
and the significant aggravation.” 86 Fed. Cl. at 144. To satisfy this requirement, petitioners
must provide “preponderant proof that the onset of symptoms occurred within a timeframe for
which, given the understanding of the disorder’s etiology, it is medically acceptable to infer
causation in-fact.” de Bazan, 539 F.3d at 1352 (citing Pafford, 451 F.3d at 1358 (Fed. Cir.
2006)). Again, for the same reasons set forth in section VI(C), petitioners failed to
preponderantly prove Prong Three of Althen, which is the last element of the Loving test.

F. Alternative Causation

Because petitioners did not meet their burden of proof on causation or significant
aggravation, respondent does not have the burden of establishing that a factor unrelated to the
vaccination caused E.O.’s injuries. See Doe v. Sec’y of Health & Human Servs., 601 F.3d
1349, 1358 (Fed. Cir. 2010) (“[petitioner] Doe never established a prima facie case, so the
burden (and attendant restrictions on what ‘factors unrelated’ the government could argue) never
shifted”). Nevertheless, respondent has identified an alternative cause of E.O.’s injuries – the
SCN1A gene mutation. Pursuant to the Vaccine Act, compensation shall be awarded where the
petitioner demonstrates the requirements set forth under the Act by a preponderance of the
evidence, and “there is not a preponderance of the evidence that the . . . injury . . . is due to
factors unrelated to the administration of the vaccine.” § 300aa-13(a)(1)(A)-(B). The Vaccine
Act provides that “factors unrelated to the administration of the vaccine,” are those “which are
shown to have been the agent . . . principally responsible for causing the petitioner’s illness,
disability, injury, condition or death.” Id. § 13(a)(2)(B).

Even if petitioners had established their case by a preponderance of the evidence, their
arguments fail because respondent has proven that the SCN1A mutation—a factor unrelated to
the administration of the vaccines—is the agent solely responsible for causing E.O.’s Dravet
syndrome and resultant neurological injuries. Compensation has been denied in a number of
similar cases 60 based upon a finding that the SCN1A mutation was a “factor unrelated to the
administration of the vaccine,” and the agent solely responsible for causing Dravet syndrome in a
child. See Deribeaux v. Sec’y of Health & Human Servs., 717 F.3d 1363 (Fed. Cir. 2013).

60
See infra note 3 for list of SCN1A cases in which compensation was denied.

32
 In the Deribeaux case, the infant, M.D., received the DTaP vaccine at about six months of
age. Deribeaux, 717 F.3d at 1364. The next day, M.D. had a prolonged seizure, and she was
ultimately diagnosed with a seizure disorder. Id. Her parents filed a case in the Vaccine
Program alleging that the DTaP vaccine triggered M.D.’s initial seizure and subsequent
neurological condition. Id. The case proceeded to hearing and the special master found that
petitioners were entitled to compensation. See Deribeaux v. Sec’y of Health & Human Servs.,
No. 05-306V, 2007 WL 4623461, at *1 (Fed. Cl. Spec. Mstr. Dec. 17, 2007) (“Deribeaux I”).
M.D. subsequently underwent genetic testing which revealed that she had an SCN1A mutation.
Deribeaux, 717 F.3d at 1363. She was then diagnosed with Dravet syndrome. Id. Based on this
evidence, respondent filed a motion to set aside the prior ruling in favor of petitioners. The case
was assigned to a different special master, who held that the evidence presented at the first
hearing established a prima facie case in favor of petitioners but that a second hearing would be
held on the issue of alternative causation. Deribeaux v. Sec’y of Health & Human Servs., No.
05-306V, 2011 WL 6935504, at *3 (Fed. Cl. Spec. Mstr. Dec. 9, 2011) (“Deribeaux II”).
Respondent was allowed to present evidence to prove that M.D.’s Dravet syndrome was caused
by the SCN1A mutation, an etiology unrelated to the vaccine, pursuant to § 300aa-13(a)(1)(A)-
(B). Id. At the hearing, respondent introduced evidence that the vaccine caused a fever,
triggering M.D.’s initial seizure, but that the cause of the seizure disorder and resulting
neurological injuries were a result of her SCN1A mutation and that the vaccine did not cause or
aggravate her condition. Id.

In Deribeaux II, the special master specifically addressed the Althen prongs and found
that the SCN1A mutation was the “sole substantial factor” in causing M.D.’s Dravet syndrome.
Id. at *33. The special master’s decision was affirmed by the Court of Federal Claims and the
Court of Appeals for the Federal Circuit, which held that the special master applied the “correct
legal standards” for proving alternative causation, as well as the three-pronged Althen analysis.
See Deribeaux, 717 F.3d 1363. Special masters have similarly denied compensation in other
SCN1A cases. The Federal Circuit’s decision in Stone v. Sec’y of Health & Human Servs., 690
F.3d 1380 (Fed. Cir. 36 2012), cert denied, 133 S. Ct. 2022 (Apr. 29, 2013), affirmed the special
master’s finding that the SCN1A gene mutation, not the DTaP vaccine, caused only a “single,
isolated initial febrile seizure,” and was thus solely responsible for the vaccinee’s SMEI. See
also Snyder v. Sec’y of Health & Human Servs., No. 07-60V, 2011 WL 2446321 (Fed. Cl. Spec.
Mstr. May 27, 2011); Harris v. Sec’y of Health & Human Servs., No. 07-59V, 2011 WL
3022544 (Fed. Cl. Spec. Mstr. May 27, 2011). The Federal Circuit upheld the special master’s
findings in Snyder v. Sec’y of Health & Human Servs., 553 F. App’x. 994, 999 (Fed. Cir. 2014),
that the “Secretary proved by preponderant evidence of its ‘factors unrelated’ defense by
showing that the gene mutations were the sole cause of the disorders.” Id. at 999.

Three SCN1A cases were recently on review at the Court of Federal Claims. In all of the
cases, the Court upheld the special masters’ denial of compensation to petitioners. In Santini v.
Sec’y of Health & Human Servs., 122 Fed. Cl. 102 (2015), the Court found that petitioners’
expert failed to provide a medical theory linking the child’s vaccination to his Dravet syndrome
and affirmed the special master’s decision denying compensation. Id. at 110.

In Barclay, the Court upheld the special master’s determination that the vaccine did not
aggravate or worsen the child’s genetic condition. Barclay v. Sec’y of Health & Human Servs.,

33
122 Fed. Cl. at 199. Likewise, in Barnette v. Sec’y of Health & Human Servs., 110 Fed. Cl. 34,
26 (2013), the special master’s finding that the child’s SCN1A mutation was the sole cause of
her Dravet syndrome and related injuries was affirmed. The Court of Federal Claims also
affirmed the special master’s finding that the child’s vaccinations did not significantly aggravate
her Dravet syndrome or any other injury. Id. Petitioners did not appeal to the Federal Circuit.

Here, respondent has put forth preponderant evidence establishing that E.O.’s SCN1A
mutation, a factor unrelated to the administration of the vaccines, is the agent solely responsible
causing his Dravet syndrome.

a. Althen Prong One: Respondent’s Medical Theory

To prove Althen Prong One establishing alternative causation, respondent is required to
set forth a medical theory explaining how a factor unrelated to the vaccine caused the injury at
issue.
Respondent’s expert, Dr. Raymond, explained the mechanism underlying Dravet
Syndrome, stating:

The gene SCN1A encodes a portion of a channel that controls the transport of sodium
molecules across cell membranes in the neurons . . . . [There is] a highly complex
chemical environment that allows the net passage of sodium from one side to another.
Mutations in the SCN1A gene have been associated with …. [SMEI] or Dravet
syndrome[,]. . . a rare condition . . . [and] . . . an animal model has been an extremely
important development in our understanding of the pathogenesis of the disease. The
model deletes one copy of the SCN1A gene and results in an animal that has spontaneous
seizures, ataxia, and premature death. Resp’s Ex. A at 7 (internal citations omitted).

The medical articles and studies filed in this case establish that the international medical
community generally agrees that vaccinations are not the cause of Dravet syndrome and that the
SCN1A mutation is responsible for causing the disease. For example, the authors of the
Brunklaus 61 study, reporting on a five year study of data collected in the United Kingdom on
patients with Dravet syndrome, describe the mutation as the “primary genetic cause” of the
disease. Pet’rs’ Ex. 55 at 2329. The authors explain that while the onset may be precipitated by
“fever/illness, vaccination or a bath . . . . the nature of the trigger has no effect on overall
developmental outcome and [] does not seem to be responsible for the subsequent
encephalopathy.” Id. at 2334.

Likewise, Professor Dr. Berten Ceulemans from the Department of Child Neurology at
the University of Antwerp, Belgium, and her colleagues conducted a clinical study 62 on 60
patients with Dravet syndrome. Dr. Ceulemans concluded that there “is a strong argument

61
Brunklaus, A., et al., “Prognostic, Clinical, and Demographic Features in SCN1A Mutation-
Positive Dravet Syndrome,” 135 BRAIN 2329-36 (2012) [Pet’rs’ Ex. 55].
62
Claes, Lieve, et al., “De Novo SCN1A Mutations Are a Major Cause of Severe Myoclonic
Epilepsy of Infancy,” 21 HUMAN MUTATION 615-21 (2003) [Resp’s Ex. A7].

34
favoring the genetic disorder itself as probably being the most important factor for
developmental problems in these [Dravet syndrome] patients.” Resp’s Ex. A7 at 4. In the
McIntosh study, the authors corrected their previous misunderstanding as to “presumed vaccine
encephalopathy” as follows:

We previously reported a retrospective analysis in which 12 of 14 patients with
presumed vaccine encephalopathy in fact had previously unrecognized Dravet
syndrome, 11 of whom had mutations in SCN1A. This showed that vaccination was
wrongly blamed as an acquired cause of a genetic disorder, and the hypothesis that
vaccination was the causal factor in our cohort could be rejected. Pet’rs’ Ex. 36 at 596.

Dr. Raymond also explained that Dr. Shafrir held an oversimplified view of splice site
mutations. Resp’s Ex. A at 9. Dr. Raymond stated that the splice mutation in E.O.’s gene is
associated with the dysfunction of the voltage-gated sodium channel, which is causally
associated with Dravet syndrome. Id. at 8. This type of deletion results in unstable mRNA and
no protein production and thus causes disease. Id. Therefore, the undersigned finds by a
preponderance of the evidence that respondent has satisfied Althen Prong One.

b. Althen Prong Two: A Logical Sequence of Cause and Effect

The second prong of Althen requires proof of a “logical sequence of cause and effect,”
showing that factors unrelated to the administration of the vaccine are responsible for causing
E.O.’s Dravet syndrome and neurological injury. E.O. developed Dravet syndrome as a result of
his genetic mutation, not because he received vaccinations. According to Dr. Raymond, even
assuming that E.O. had an earlier onset of his seizure disorder, this would not alter his clinical
course or outcome. Resp’s Ex. E at 4. As explained by Dr. Sachdeo, “There is no evidence that
… [E.O.] would not have developed Dravet syndrome regardless of having received [a]
vaccination.” Resp’s Ex. C at 5. Dr. Raymond and Dr. Sachdeo rely on the McIntosh and
Brunklaus articles, respectively, in support of their propositions. Dr. Raymond also testified that
E.O.’s SCN1A mutation is the “sole cause” of his seizure disorder, developmental delay, and all
of the other features of Dravet syndrome. Resp’s Ex. A at 8, 13. Both Dr. Raymond and Dr.
Sachdeo opine that it is not necessary to invoke an environmental factor, like the vaccination, to
explain E.O.’s condition. Id.; Resp’s Ex. C at 6. The undersigned thus finds by a preponderance
of the evidence that respondent has satisfied Althen Prong Two.

c. Althen Prong Three: Timing

The last element of causation is proof of a proximate temporal relationship between the
gene mutation and the injury. Althen, 418 F. 3d at 1278. E.O.'s alleged injury is his Dravet
syndrome and his resulting neurological complications. Petitioners frame the injury here as
vaccine-caused and/or vaccine-aggravated Dravet syndrome. In reality, the only temporal
relationship is between the vaccination and E.O.’s initial seizure. E.O. did not manifest the
criteria for Dravet syndrome until he was over 21 months old, and thus there is no temporal
relationship between his vaccinations and the onset of his Dravet syndrome. Moreover, E.O. had
no encephalopathy after the vaccinations at issue. Therefore, E.O. did not have an injury that
was temporally associated with the vaccines on April 9, 2009. His initial seizure was, in

35
hindsight, a suspicious sign that he might develop Dravet syndrome, or the initial manifestation
of his genetic mutation. That fact alone does not establish a vaccine-related injury.
Respondent’s experts, on the other hand, state that E.O.’s clinical course, timing of the onset of
his initial seizure, and overall outcome were consistent with Dravet syndrome. Therefore, the
undersigned finds by a preponderance of the evidence that respondent has satisfied Althen Prong
Three.

VII. Conclusion

For the reasons discussed above, the undersigned finds that petitioners have not
established entitlement to compensation and that their petition must therefore be dismissed. 63 In
the absence of a timely filed motion for review filed pursuant to Vaccine Rule 23, the Clerk of
Court SHALL ENTER JUDGMENT consistent with this decision.

IT IS SO ORDERED.

s/Nora Beth Dorsey
Nora Beth Dorsey
Chief Special Master

63
As discussed in note 3 above, there have been at least 15 other Program cases involving
alleged vaccine injuries which were found to be attributable to SCN1A mutations. In the
absence of further medical and/or scientific developments in such cases, the undersigned is
unlikely to be persuaded of vaccine causation. Likewise, the undersigned will be disinclined to
find a reasonable basis to compensate the attorneys and/or experts involved in such cases.

36